<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">108925</article-id>
<article-id pub-id-type="doi">10.7554/eLife.108925</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.108925.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Microbiology and Infectious Disease</subject>
</subj-group>
</article-categories><title-group>
<article-title>Nanoscopy Reveals Heparan Sulfate Clusters as Docking Sites for SARS-CoV-2 Attachment and Entry</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8451-8592</contrib-id>
<name>
<surname>Han</surname>
<given-names>Sue</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Tiansheng</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mohseni</surname>
<given-names>Ammar</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kosik</surname>
<given-names>Ivan</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6726-5087</contrib-id>
<name>
<surname>Chan</surname>
<given-names>Chung Yu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>López-Muñoz</surname>
<given-names>Alberto Domingo</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matthias</surname>
<given-names>Jessica</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Suddaby</surname>
<given-names>Reid</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0879-5728</contrib-id>
<name>
<surname>Wang</surname>
<given-names>Zhixiong</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3826-1081</contrib-id>
<name>
<surname>Jin</surname>
<given-names>Albert J</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wurm</surname>
<given-names>Christian A</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3826-1906</contrib-id>
<name>
<surname>Yewdell</surname>
<given-names>Jonathan W</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<email>jyewdell@nih.gov</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wu</surname>
<given-names>Ling-Gang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>wul@ninds.nih.gov</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01s5ya894</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043z4tv69</institution-id><institution>Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution>Abberior Instruments America LLC</institution>, <city>Bethesda</city>, <country country="US">United States</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00372qc85</institution-id><institution>Intramural Research Program, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health</institution></institution-wrap>, <city>Bethesda</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Schoggins</surname>
<given-names>John W</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7944-6800</contrib-id><role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution>
</institution-wrap>
<city>Dallas</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Schoggins</surname>
<given-names>John W</given-names>
</name>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7944-6800</contrib-id><role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution>
</institution-wrap>
<city>Dallas</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>*</label><p>Equal contribution</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: All authors except Jessica Matthias and Christian A. Wurm declare no competing interests. Jessica Matthias and Christian A. Wurm work for Abberior Instruments America LLC, Bethesda, MD, United States, which commercializes the MINFLUX microscope.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-11-14">
<day>14</day>
<month>11</month>
<year>2025</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP108925</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-09-08">
<day>08</day>
<month>09</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-09-11">
<day>11</day>
<month>09</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.09.08.674976"/>
</event>
</pub-history>
<permissions>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
<ali:license_ref>https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref>
<license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-108925-v1.pdf"/>
<abstract>
<p>Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin- converting enzyme 2 (ACE2) is widely assumed as the receptor. Using advanced light microscopy to resolve individual virions and receptors, we found instead that heparan sulfate (HS), not ACE2, mediates SARS-CoV-2 cell-surface attachment and subsequent endocytosis. ACE2 functions only downstream of HS to enable viral genome expression. Instead of binding single HS molecules that electrostatically interact with viral surface proteins weakly, SARS-CoV-2 binds clusters of ∼6–137 HS molecules projecting 60–410 nm above the plasma membrane. These tall, HS-rich clusters, present at about one per 6 μm², act as docking sites for viral attachment. Blocking HS binding with the clinically used HS- binding agent pixantrone strongly inhibited the clinically relevant SARS-CoV-2 Omicron JN.1 subvariant from attaching to and infecting human airway cells. This work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting downstream, thereby identifying HS interactions as a key anti-COVID-19 strategy. This paradigm and its therapeutic implications may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.</p>
</abstract>
<abstract abstract-type="summary">
<title>Statement of Significance</title>
<p>Viral entry, a crucial antiviral target, is typically thought to involve binding its unique receptor for the cell surface attachment and subsequent entry. We examined this concept with advanced microscopies to resolve individual receptors and SARS-CoV-2 virions responsible for the COVID-19 pandemic. We discovered two receptors for viral entry: heparan sulfate, a polysaccharide that may bind many viruses, mediates viral attachment and subsequent endocytosis, whereas angiotensin-converting enzyme 2 (ACE2), the generally assumed SARS-CoV-2 receptor, acts only downstream to facilitate viral infection. This new model suggests perturbation of HS binding as a more effective anti-COVID-19 strategy than previously recognized. It may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Understanding how viruses enter host cells is essential for developing effective vaccines and therapies. It is widely believed that viral entry is based on binding a single receptor that also facilitates subsequent viral membrane penetration. Decades of research suggest that heparan sulfate, a linear sulfated anionic polysaccharide covalently linked to cell-surface proteoglycans in most cell types, can facilitate attachment of viruses and bacteria by virtue of negative charge interaction with basic virion surface amino acids (<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>). It is thought that viruses exploit weakly interacting with HS to augment the chance of contacting a more specific, high-affinity cell surface entry receptor (<xref ref-type="bibr" rid="c3">3</xref>).</p>
<p>A prominent contemporary example of this model is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. SARS-CoV-2 is thought to use human angiotensin- converting enzyme 2 (hACE2) as its receptor, based on spike protein (S) high affinity binding to hACE2, and the requirement of hACE2 for infection (<xref ref-type="bibr" rid="c4">4</xref>–<xref ref-type="bibr" rid="c8">8</xref>). HS binds S <italic>in vitro</italic> enhancing the open conformation of the receptor-binding domain (<xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c7">7</xref>). Perturbating HS significantly reduces SARS-CoV-2 infection in many cell types (<xref ref-type="bibr" rid="c9">9</xref>–<xref ref-type="bibr" rid="c11">11</xref>). These results led to the widely accepted view that SARS-CoV-2 attachment is mediated by SARS-CoV-2 binding to cell surface hACE2, which can be significantly enhanced by the attachment factor HS (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c9">9</xref>–<xref ref-type="bibr" rid="c11">11</xref>).</p>
<p>Based on similar experimental results, HS is thought to facilitate the binding of other CoVs to cell surface hACE2 (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>). This includes SARS-CoV, responsible for the SARS outbreak two decades ago, and human coronavirus NL63, a cause of the common cold (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>). HS is also considered an attachment factor for medically important non-CoVs including hepatitis C, HIV, Ebola, papilloma, and herpes viruses (<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>).</p>
<p>Together, these studies establish HS as an important factor for a broad range of viruses (and other pathogens) that augments pathogen binding with specific cognate cell surface receptors. However, to our knowledge, there is no direct, high-resolution microscopic evidence demonstrating that viruses, including SARS-CoV-2, bind their specific receptors at the cell surface, and not for example, only after internalization into an endosome. Here, we address this decisive lacuna in the currently accepted model for SARS-CoV-2 entry.</p>
<p>To this end, we employed several advanced microscopic methods to achieve unprecedented precision in defining SARS-CoV-2 entry. Using confocal microscopy, stimulated emission depletion microscopy (STED) at ∼60 nm resolution (<xref ref-type="bibr" rid="c14">14</xref>), and minimal photon flux nanoscopy (MINFLUX) at ∼1-3 nm localization precision (<xref ref-type="bibr" rid="c15">15</xref>, <xref ref-type="bibr" rid="c16">16</xref>), and electron microscopy (EM), we show that HS, not hACE2 (<xref ref-type="bibr" rid="c4">4</xref>), is the receptor for SARS-CoV-2 cell-surface attachment and endocytic internalization. Virions exclusively dock at HS clusters that may protrude hundreds of nanometers from the plasma membrane. Internalized virions then bind endosomal hACE2 to deliver viral cores to the cytosol to initiate infection. Blocking HS binding with a clinically used HS-binding agent leads to substantial inhibition of clinically relevant authentic SARS-CoV-2 infection in primary human airway cells. These findings suggest perturbing S-HS binding as a broadly effective strategy for blocking infection by SARS-CoV-2 and other viruses that rely on HS clusters for internalization.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Pseudotyped SARS-CoV-2 internalization is independent of ACE2</title>
<p>To observe the virus entering cells and replication, we first used a replicative recombinant vesicular stomatitis virus (VSV) expressing EGFP (infection indicator) and Wuhan-hu-1 SARS- CoV-2 S in place of the natural G receptor/fusion protein (<xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref>) (VSV<italic><sub>EGFP</sub></italic>-S, <xref rid="fig1" ref-type="fig">Fig. 1A</xref>). VSV<italic><sub>EGFP</sub></italic>-S virus was amplified in Vero or BHK<sub>hACE2</sub> cells. The amplified VSV<italic><sub>EGFP</sub></italic>-S virus was concentrated for purification. The purified VSV<italic><sub>EGFP</sub></italic>-S was labeled with Alexa or Atto dyes (e.g., Alexa Flour 647 NHS ester, abbreviated as A647) via primary amines (<xref ref-type="bibr" rid="c19">19</xref>) (e.g., VSV<italic><sub>EGFP</sub></italic>- S-A647, <xref rid="fig1" ref-type="fig">Fig. 1A</xref>, see Methods) for seeing virions entering cells. VSV<italic><sub>EGFP</sub></italic>-S-A647 virions attached to glass showed that nearly all viral A647 (V-A647) spots overlapped with immunolabeled S puncta (92.96 ± 0.02%, 606 particles, <xref rid="fig1" ref-type="fig">Fig. 1A</xref>). This result suggests that the purified fluorescent V-A647 spots reflect VSV<italic><sub>EGFP</sub></italic>-S-A647 virions, rather than non-S-containing fluorescent spots (e.g., VSV<italic><sub>EGFP</sub></italic>-A647). We used similar methods to label other recombinant or authentic SARS-CoV-2 virions with various Alexa/Atto dyes (see Methods).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Fig 1.</label>
<caption><title>hACE2-independent internalization of pseudo-typed SARS-CoV-2.</title>
<p><bold>A, Upper:</bold> Schematic drawing of a pseudo-typed SARS-CoV-2 virion, VSV<italic><sub>EGFP</sub></italic>-S-A647, in which the <italic>EGFP</italic>-coding sequence was inserted into the genomic RNA of VSV, the G protein of VSV was replaced with S of SARS-CoV-2, and A647 was conjugated with primary amines of superficial envelop proteins. <bold>Lower:</bold> Confocal images of A647 of purified VSV<italic><sub>EGFP</sub></italic>-S-A647 (V-A647, red) on coverslips and immunofluorescent staining with antibody against S2 subunit of S-protein (green). <bold>B,</bold> Bright-field and confocal images of VSV<italic><sub>EGFP</sub></italic>-S-A647’s A647 (V-A647) and <italic>EGFP</italic> expression (<italic>V-EGFP</italic>) in BHK21 cells stably expressing hACE2 (BHK<sub>hACE2</sub>), BHK21 cells without ACE2 expression (BHK), and BHK cells transiently overexpressed with hACE2- BFP plasmid (BHK+hACE2). Top: Incubation protocol – cells were incubated with VSV<italic><sub>EGFP</sub></italic>-S-A647 for 1 h at 37°C, followed by washout for 24 h (applies to panels B-G). <bold>C,</bold> The white dotted box in panel B enlarged to show V-A647 spots in EGFP-labelled cytosol. <bold>D,</bold> Similar to panel B, except in 293T<sub>hACE2</sub> and 293T cells. <bold>E,</bold> Similar to panel B, except in Vero (containing ACE2), Hela (no ACE2) and MRC5 (no ACE2) cells. <bold>F,</bold> Similar to panel B, except VSV<italic><sub>EGFP</sub></italic>-S-A647 was replaced with Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647. <bold>G,</bold> Fluorescence intensity of VSV<italic><sub>EGFP</sub></italic>-S-A647’s V-A647 (F<sub>647</sub>) and <italic>V-EGFP</italic> (F<italic><sub>EGFP</sub></italic>) in BHK<sub>hACE2</sub> (471 cells, 3 experiments), BHK (370 cells, 3 experiments), BHK+hACE2 (515 cells, 3 experiments). 293T<sub>hACE2</sub> (404 cells, 3 experiments), 293T (234 cells, 3 experiments), Vero (295 cells, 3 experiments), Hela (305 cells, 3 experiments), and MRC5 (237 cells, 3 experiments) cells. Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647’s F<sub>647</sub> and F<italic><sub>EGFP</sub></italic> in BHK<sub>hACE2</sub> (364 cells, 3 experiments) and BHK (335 cells, 3 experiments) cells are also plotted. Virus incubation protocol is shown in panel B. F<sub>647</sub>: mean ± s.e.m., reflecting viral uptake; F<italic><sub>EGFP</sub></italic>: mean ± s.e.m., reflecting viral infection. F<sub>647</sub> and F<italic><sub>EGFP</sub></italic> were measured per cell identified in the bright field and were normalized to cells expressing ACE2 in each subgroup (see gaps between subgroups). ***: p &lt; 0.001, t-test.</p></caption>
<graphic xlink:href="674976v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>4-24 h after 1 h VSV<italic><sub>EGFP</sub></italic>-S-A647 incubation with cells at 37°C (protocol in <xref rid="fig1" ref-type="fig">Fig. 1B</xref>), viral <italic>EGFP</italic> (<italic>V-EGFP</italic>) expression, which indicates viral genome expression, was observed in various ACE2-expressing cells, including hACE2-stably-expressed BHK21 (BHK<sub>hACE2</sub>) or 293T cells (293T<sub>hACE2</sub>), and Vero cells expressing ACE2 endogenously; in contrast, <italic>V-EGFP</italic> was not expressed in non-ACE2-expressing cells, including BHK21 (BHK), 293T, Hela and MRC5 cells (<xref rid="fig1" ref-type="fig">Figs. 1B-G</xref> and S1). Similarly, flow cytometric measurements of V-EGFP fluorescence from many thousand cells showed <italic>V-EGFP</italic> expression in BHK<sub>hACE2</sub> but not BHK cells (<xref ref-type="supplementary-material" rid="supp1">Fig. S2</xref>). Transient hACE2 overexpression restored <italic>V-EGFP</italic> expression in BHK cells (<xref rid="fig1" ref-type="fig">Figs. 1B-lower and 1G</xref>). These results confirmed the hACE2-dependence of SARS-CoV-2 infection (<xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c7">7</xref>, <xref ref-type="bibr" rid="c20">20</xref>–<xref ref-type="bibr" rid="c22">22</xref>).</p>
<p>Surprisingly, V-A647 spot intensity and distribution were independent of ACE2 in the seven cell lines tested (<xref rid="fig1" ref-type="fig">Figs. 1B-E</xref>, summarized in <xref rid="fig1" ref-type="fig">Figs. 1G</xref> and S1). Confocal sectioning revealed that these V-A647 spots were in the cytoplasm (<xref rid="fig1" ref-type="fig">Figs. 1C</xref> and S3), suggesting that VSV<italic><sub>EGFP</sub></italic>-S-A647 internalization is independent of ACE2.</p>
<p>Extending these observations, incubating BHK<sub>hACE2</sub> or BHK cells with Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>- A647 an A647-labeled, <italic>EGFP</italic>-expressing lentivirus (Lenti<italic><sub>EGFP</sub></italic>) pseudotyped with S-protein omicron variant (S<sub>omi</sub>), revealed similar hACE2-dependent <italic>EGFP</italic> expression, but hACE2- independent virion internalization (<xref rid="fig1" ref-type="fig">Figs. 1F</xref>, <xref rid="fig1" ref-type="fig">1G</xref> and S1). While showing that VSV-S and Lenti- S<sub>Omi</sub> infection is hACE2-dependent as expected, these results revealed surprisingly that VSV-S and Lenti-S<sub>Omi</sub> internalization is hACE2-independent.</p>
</sec>
<sec id="s2b">
<title>Endocytic internalization is the main viral infection pathway</title>
<p>Given that hACE2 is required for the fusogenic activity of pseudotyped or authentic SARS-CoV-2 (<xref ref-type="bibr" rid="c4">4</xref>), the hACE2-independent internalization of V-A647 spots from VSV<italic><sub>EGFP</sub></italic>-S-A647 or Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647 (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) may reflect endocytic internalization. Four lines of evidence described below strengthen this suggestion.</p>
<p>First, to track endocytic vesicles, we included a fluorescent dye, Atto 490LS (A490), in the bath solution, which can be taken up by endocytosis into, and thus label, the endocytic vesicle (Figs. S3A and 2A) (<xref ref-type="bibr" rid="c23">23</xref>, <xref ref-type="bibr" rid="c24">24</xref>). BHK<sub>hACE2</sub> or BHK cells were incubated with VSV<italic><sub>EGFP</sub></italic>-S- A647 plus A490 in the bath solution for 1 h at 37°C, followed by washout. 24 h later, we found near complete colocalization of cytoplasmic V-A647 with A490 spots in either BHK<sub>hACE2</sub> or BHK cells (<xref ref-type="supplementary-material" rid="supp1">Fig. S3A-C</xref>). This result suggests that endocytosis takes up both the virus and the bath A490 in an ACE2-independent manner.</p>
<p>Second, we adsorbed VSV<italic><sub>EGFP</sub></italic>-S-A647 to BHK<sub>hACE2</sub> or BHK cells for 1 h at 4°C to prevent endocytosis (cold temperature prevents endocytosis) and then incubated cells with A490 at 37°C for 3 min to allow for, and thus image, endocytic vesicle formation within 3 min (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>). STED microscopy showed that most V-A647 spots contained no A490, but colocalized with the plasma membrane (PM) (<xref ref-type="supplementary-material" rid="supp1">Fig. S4, </xref>14 cells, 4 cultures) and thus labeled the cell outline. Inside this outline, V-A647 spots colocalized with A490 spots in either BHK<sub>hACE2</sub> or BHK cells, indicating ACE2-independent endocytic uptake of the virus with the bath A490 as early as 3 min (11 cells, 3 experiments; <xref rid="fig2" ref-type="fig">Fig. 2A-C</xref>). Consistent with this observation, prolonged washout (4-24 h) completely depleted V-A647 at the cell-surface outline while increasing cytoplasmic V-A647 (<xref rid="fig1" ref-type="fig">Fig. 1B-F</xref>), suggesting that surface-attached virions are taken up by endocytosis within 4 h.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Fig 2.</label>
<caption><title>Endocytosis is the primary route for pseudo-typed SARS-CoV-2 internalization and gene expression.</title>
<p><bold>A, Left upper:</bold> incubation protocol for viral attachment and early endocytosis – incubating cells with VSV<italic><sub>EGFP</sub></italic>-S-A647 for 1 h at 4°C, followed by 3 min washout with 500-750 μM A490 at 37°C (applies to panel A-D). <bold>Left lower:</bold> strategy for labeling endocytic vesicles taking up PM-attached virions (VSV<italic><sub>EGFP</sub></italic>-S-A647, red) with a fluorescent dye in the bath (A490, cyan). <bold>Right:</bold> STED images showing V-A647 spots (red dots) colocalization with A490 spots (cyan) in the cytoplasm (cell boundary beyond the plot). <bold>B</bold>, STED XY-plane images of V-A647 and A490 at different Z sections as labeled showing a cytosolic A490 spot (endocytic vesicle) containing a single V-A647 spot that reflects a single VSV-S virion. <bold>C,</bold> STED XY-plane images of V-A647 and A490 showing a cytosolic A490 spot may contain 1- 4 V-A647 spots, each reflecting a single virion. Top: the V-A647 spot number (N<sub>A647</sub>) is labeled. <bold>D, Left:</bold> W<sub>H</sub> distribution of A490 spots (Spot<sub>A490</sub>) containing V-A647 spots (55 Spot<sub>A490</sub>, 3 experiments from BHK cells). <bold>Middle:</bold> N<sub>A647</sub> plotted versus the corresponding Spot<sub>A490</sub> W<sub>H</sub> (55 Spot<sub>A490</sub>, 3 experiments, from BHK cells). A linear regression fit (correlation coefficient: 0.53) showed that larger Spot<sub>A490</sub> contains more V-A647 spots. <bold>Right:</bold> V-A647-containing Spot<sub>A490</sub> W<sub>H</sub> in BHK<sub>hACE2</sub> (70 Spot<sub>A490</sub>, 3 experiments) and BHK cells (55 Spot<sub>A490</sub>, 3 experiments). <bold>E, Left:</bold> EM images showing that endosomes may contain one or more VSV<italic><sub>EGFP</sub></italic>-S-A647 virions (arrows). Incubation protocol: VSV<italic><sub>EGFP</sub></italic>-S-A647 for 1 h at 4°C, 15 min washout at 37°C. <bold>Right:</bold> W<sub>H</sub> (mean ± s.e.m.) of EM-observed virus (VSV<italic><sub>EGFP</sub></italic>-S-A647)-containing endosome (38 endosomes, 2 experiments) and STED-observed virus (VSV<italic><sub>EGFP</sub></italic>-S-A647)-containing Spot<sub>A490</sub> (70 Spot<sub>A490</sub>, 3 experiments). <bold>F,</bold> Bright field and confocal images of V-A647 (uptake) and <italic>V-EGFP</italic> (viral gene expression) in BHK<sub>hACE2</sub> cells in control (Ctrl) or treated with dynasore (DnS, 80 μM, bath). Top: VSV<italic><sub>EGFP</sub></italic>-S-A647 incubation protocol – 1 h incubation, 24 h washout, all at 37°C. <bold>G,</bold> VSV<italic><sub>EGFP</sub></italic>-S-A647’s F<sub>647</sub> (uptake) and F<italic><sub>EGFP</sub></italic> (gene expression) in cells in Ctrl (789 cells, 3 experiments), treated with DnS (653 cells, 3 experiments), or overexpressed with dynamin 2 K44A (19 cells, 2 experiments). Virus incubation protocol shown in panel F. **: p &lt; 0.01; ***: p &lt; 0.001, t-test. <bold>H, Left:</bold> bright field and confocal images of V-A647 (uptake) in BHK<sub>hACE2</sub> cells in Ctrl or treated with cathepsin inhibitor 1 (CPS Inh, 10 μM). Top: VSV<italic><sub>EGFP</sub></italic>-S-A647 incubation protocol – 1 h incubation at 37°C. <bold>Right:</bold> bright field and confocal images of V-A647 (uptake) and <italic>V-EGFP</italic> (gene expression) in BHK<sub>hACE2</sub> cells in Ctrl or treated with CPS Inh. Top: VSV<italic><sub>EGFP</sub></italic>-S-A647 incubation protocol – 1 h incubation, 24 h washout, all at 37°C. <bold>I,</bold> F<sub>647</sub> (uptake) or F<italic><sub>EGFP</sub></italic> (gene expression) in cells in Ctrl (540 cells, 3 experiments) or treated with CPS Inh (742 cells, 3 experiments). F<sub>647</sub> and F<italic><sub>EGFP</sub></italic>were measured after VSV<italic><sub>EGFP</sub></italic>-S- A647 incubation in panel H-left and H-right, respectively. ***: p &lt; 0.001, t-test.</p></caption>
<graphic xlink:href="674976v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Third, 3D-STED imaging showed that A490-labeled vesicle’s full-width-half-maximums (W<sub>H</sub>) was ∼333-363 nm (range: 149 - 658 nm) in BHK<sub>hACE2</sub> or BHK cells (<xref rid="fig2" ref-type="fig">Fig. 2B-D</xref>). As W<sub>H</sub> increased, V-A647 spot number per vesicle increased from 1 to 5 (<xref rid="fig2" ref-type="fig">Figs. 2B</xref> and <xref rid="fig2" ref-type="fig">2C</xref>). V-A647 spots appeared cylinder-shaped (length: 135-224 nm) or round-shaped (W<sub>H</sub>: 74-118 nm) (<xref rid="fig2" ref-type="fig">Figs. 2B</xref> and <xref rid="fig2" ref-type="fig">2C</xref>). The cylinder shape is consistent with ∼180×70 nm bullet-shaped VSV virions (<xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c25">25</xref>), whereas the round shape may reflect the cross-section of the cylinder shape.</p>
<p>Thin-section (70 nm) EM showed endosome-like structures with a diameter of 365 ± 28 nm (Range: 115 - 789 nm; 38 structures) containing 1-3 virions with the expected width and length of VSV (<xref ref-type="bibr" rid="c19">19</xref>, <xref ref-type="bibr" rid="c25">25</xref>) (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>). The EM-measured diameter of endosomes containing virions was similar to the STED-measured W<sub>H</sub> of A490-labeled vesicles containing V-A647 spots (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>), strengthening the STED observation of endocytic vesicles. The EM- observed maximal virion number (<xref ref-type="bibr" rid="c3">3</xref>) in an endosome was less than the STED-observed (<xref ref-type="bibr" rid="c5">5</xref>), likely because we counted virions only in one thin section with EM, but the entire A490-labeled vesicle with 3D-STED microscopy.</p>
<p>The large size (115 - 789 nm) of the virus-containing vesicles observed with STED and EM implies macropinocytosis that may form large vesicles engulfing multiple virions. Our observation is consistent with a recent study showing that a macropinocytosis inhibitor 5-[N- ethyl-N-isopropyl] amiloride (EIPA) (<xref ref-type="bibr" rid="c26">26</xref>) reduces SARS-CoV-2 replication in Vero cells (<xref ref-type="bibr" rid="c27">27</xref>).</p>
<p>Fourth, dynasore or dominant-negative dynamin 2-K44A overexpression, which inhibits fission of dynamin-dependent endocytosis (<xref ref-type="bibr" rid="c28">28</xref>–<xref ref-type="bibr" rid="c30">30</xref>), substantially reduced V-A647 internalized 1- 24 h after viral incubation (<xref rid="fig2" ref-type="fig">Fig. 2F-G</xref>). This result suggests that viruses are internalized via dynamin-dependent endocytosis.</p>
<p>In addition to inhibiting V-A647 endocytosis, dynasore or dynamin 2-K44A inhibited <italic>V- EGFP</italic> expression 24 h after virus incubation by ∼66-77% (<xref rid="fig2" ref-type="fig">Fig. 2F-G</xref>), suggesting that endocytosis is the main route for viral genome expression. Further strengthening this suggestion, cathepsin inhibitor 1, which inhibits endosomal cathepsin L crucial for SARS-CoV-2 endosomal fusion and infection (<xref ref-type="bibr" rid="c31">31</xref>–<xref ref-type="bibr" rid="c34">34</xref>), nearly abolished <italic>V-EGFP</italic> expression without affecting V-A647 uptake (<xref rid="fig2" ref-type="fig">Fig. 2H</xref> and <xref rid="fig2" ref-type="fig">2I</xref>). We concluded that endocytic internalization is the major pathway for pseudotyped SARS-CoV-2 genome expression.</p>
</sec>
<sec id="s2c">
<title>Heparan sulfate, but not hACE2, is required for viral cell-surface attachment and internalization</title>
<p>Four sets of evidence suggest that heparan sulfate (HS), but not hACE2, is the receptor underlying VSV-S cell-surface attachment. First, VSV-S and Lenti-S<sub>Omi</sub> internalization is hACE2-independent (<xref rid="fig1" ref-type="fig">Figs. 1</xref> and S1), implying that the cell-surface attachment of these viruses is independent of hACE2. Second, with 1 h viral incubation at 4°C for virus attachment at the cell surface, V-A647 intensity at the cell surface was similar between BHK<sub>hACE2</sub> cells that contained hACE2 at the cell surface and BHK cells that did not contain hACE2 (<xref rid="fig3" ref-type="fig">Figs. 3A</xref> and <xref rid="fig3" ref-type="fig">3B</xref>), revealing hACE2-independent viral cell-surface attachment. Further supporting this conclusion, flow cytometric measurements from many thousand cells showed similar V-A647 intensity between BHK<sub>hACE2</sub> and BHK cells after 1 h viral incubation at 4°C for viral cell-surface attachment (<xref ref-type="supplementary-material" rid="supp1">Fig. S5</xref>). Third, 93-94% V-A647 spots colocalized with immunolabelled HS spots in BHK<sub>hACE2</sub> (94 ± 2%, 8 cells) and BHK (93 ± 2%, 8 cells) cells (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>), indicating hACE2- independent VSV-S colocalization with HS. HS spots may thus serve as the docking site for VSV-S attachment at the cell surface. Fourth, heparinase I/II/III mixture (HPRase), which nearly abolished cell-surface immunolabelled HS (<xref rid="fig3" ref-type="fig">Fig. 3D</xref>) (<xref ref-type="bibr" rid="c35">35</xref>), reduced cell-surface V-A647 by ∼83- 85% in both BHK<sub>hACE2</sub> and BHK cells (after 1 h viral incubation at 4°C for viral cell-surface attachment, <xref rid="fig3" ref-type="fig">Fig. 3E</xref>), suggesting that HS crucial for VSV-S cell-surface attachment. Application of HPRase also reduced intracellular V-A647 spots by ∼81-82% in both BHK<sub>hACE2</sub> and BHK cells, suggesting that HS-mediated viral attachment is a critical step preceding viral endocytosis (<xref rid="fig3" ref-type="fig">Fig. 3F</xref>; incubation protocol: 1 h virus incubation at 4°C for viral attachment, followed by 1 h washout at 37°C for viral uptake). Further, HPRase reduced <italic>V-EGFP</italic> expression in BHK<sub>hACE2</sub> cells by ∼79%, suggesting that HS-mediated viral attachment is a critical step preceding viral genome expression (24 h after virus incubation, <xref rid="fig3" ref-type="fig">Fig. 3G</xref>). In summary, these results (<xref rid="fig3" ref-type="fig">Fig. 3A-G</xref>) suggest that HS binding with VSV-S underlies viral cell-surface attachment, which is crucial for the subsequent virus endocytosis and genome expression.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Fig 3.</label>
<caption><title>Heparan sulfate is the receptor for pseudo-typed SARS-CoV-2 attachment at the cell surface.</title>
<p><bold>A,</bold> Immunolabelling (A647) of hACE2 in a BHK<sub>hACE2</sub> (left) and a BHK (right) cell. <bold>B,</bold> ACE2-independent viral cell-surface attachment. <bold>Images:</bold> STED images showing virus cell-surface attachment in a BHK<sub>hACE2</sub> (left) or BHK (right) cell. Middle: images in green (left) and yellow (right) boxes replotted on a larger scale. Top: incubation protocol – virus (VSV<italic><sub>EGFP</sub></italic>-S-A490) 1 h at 4°C for viral attachment at the cell surface (applies to panels B, C, E, and H). <bold>Bar graph:</bold> Cell-surface virus fluorescence intensity (F<sub>Virus</sub>) per BHK<sub>hACE2</sub> (92 cells, 3 experiments) or BHK cell (98 cells, 3 experiments). Data normalized to the mean of the BHK<sub>hACE2</sub> group. <bold>C,</bold> Cell-surface-attached viruses colocalized with HS puncta. <bold>Images:</bold> STED images of viral spots (VSV<italic><sub>EGFP</sub></italic>-S-A490’s V-A490) and immunolabelled HS (Alexa 488-conjugated antibody) at BHK<sub>hACE2</sub> or BHK cell surface. Top: incubation protocol – VSV<italic><sub>EGFP</sub></italic>-S-A647 1 h at 4°C for cell-surface attachment. <bold>Bar graph:</bold> the percentage of viral spots overlapping with HS puncta in BHK<sub>hACE2</sub> (8 cells, 4 experiments) or BHK cells (8 cells, 4 experiments). <bold>D,</bold> Bright field and confocal images of immunolabelled HS (left) and HS fluorescence intensity (F<sub>HS</sub>, right) in BHK<sub>hACE2</sub> cells in Ctrl (188 cells, 3 experiments) or treated with Heparinases I/II/III (HPRase, 264 cells, 3 experiments). ***: p &lt; 0.001, t-test. <bold>E, Images:</bold> bright field and confocal image of V-A647 in BHK<sub>hACE2</sub> cells in Ctrl or treated with HPRase. Top: incubation protocol – VSV<italic><sub>EGFP</sub></italic>-S-A647 1 h at 4°C for cell-surface attachment. <bold>Bar graph:</bold> cell-surface F<sub>647</sub> per cell for BHK<sub>hACE2</sub> cells (left) in Ctrl (125 cells, 3 experiments) or treated with HPRase (150 cells, 3 experiments), and for BHK cells (right) in Ctrl (147 cells, 3 experiments) or treated with HPRase (127 cells, 3 experiments). ***: p &lt; 0.001, t-test. <bold>F, Images:</bold> bright field and confocal image of V-A647 (uptake) in BHK<sub>hACE2</sub> cells in Ctrl or treated with HPRase. Top: incubation protocol – VSV<italic><sub>EGFP</sub></italic>-S-A647 1 h at 4°C (for viral attachment), 1 h washout at 37°C (for endocytosis of cell-surface-attached viruses). ***: p &lt; 0.001, t-test. <bold>Bar graph:</bold> F<sub>647</sub> (uptake) for BHK<sub>hACE2</sub> cells in Ctrl (201 cells, 3 experiments) or treated with HPRase (197 cells, 3 experiments), and for BHK cells in Ctrl (202 cells, 3 experiments) or treated with HPRase (206 cells, 3 experiments). <bold>G, Images:</bold> bright field and confocal image of <italic>V-EGFP</italic> expression in BHK<sub>hACE2</sub> cells in control or treated with HPRase. Top: incubation protocol – VSV<italic><sub>EGFP</sub></italic>-S-A647 1 h at 4°C, 24 h washout at 37°C. ***: p &lt; 0.001, t-test. <bold>Bar graph:</bold> F<sub>EGFP</sub> (viral gene expression) per BHK<sub>hACE2</sub> cell in Ctrl (482 cells, 3 experiments) or treated with HPRase (391 cells, 3 experiments). <bold>H,</bold> STED images of viral spots (VSV<italic><sub>EGFP</sub></italic>-S-A490’s A490) and immunolabeled hACE2 puncta (A647) at a BHK<sub>hACE2</sub> cell surface. <bold>I,</bold> STED images of viral spots (VSV<italic><sub>EGFP</sub></italic>-S-A490’s A490) and immunolabeled hACE2 puncta (A647) inside BHK<sub>hACE2</sub> cells – hACE2 is sometimes taken up with viruses in endosomes.</p></caption>
<graphic xlink:href="674976v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>hACE2 acts downstream of endocytosis to promote viral infection</title>
<p>We showed that hACE2 is essential for viral genome expression but not cell-surface viral attachment or endocytosis (<xref rid="fig1" ref-type="fig">Figs. 1</xref>-<xref rid="fig3" ref-type="fig">3</xref>), suggesting that hACE2 acts downstream of endocytosis. Unlike HS spots, only 22 ± 2% cell-surface V-A647 spots colocalized with hACE2 spots in BHK<sub>hACE2</sub> cells (<xref rid="fig3" ref-type="fig">Fig. 3H</xref>; 13 cells, 2 experiments). However, 38 ± 3% cell-surface V-A647 spots were within 200 nm from neighboring hACE2 spots (<xref rid="fig3" ref-type="fig">Fig. 3H</xref>, 13 BHK<sub>hACE2</sub> cells, 2 experiments). These virions and hACE2 may be packed into the same (large) vesicle, as we noted that 38 ± 5% intracellular V-A647 spots colocalized with or within 200 nm from hACE2 spots (13 BHK<sub>hACE2</sub> cells, 2 experiments; <xref rid="fig3" ref-type="fig">Fig. 3I</xref>). These results suggest that hACE2’s infection role may be due to cell-surface hACE2 co-internalization with virions to facilitate cathepsin L- dependent (<xref rid="fig2" ref-type="fig">Fig. 2H-I</xref>) (<xref ref-type="bibr" rid="c31">31</xref>–<xref ref-type="bibr" rid="c34">34</xref>) viral fusion at the endosomal membrane.</p>
</sec>
<sec id="s2e">
<title>VSV-S recapitulates the SARS-Cov-2 entry pathway</title>
<p>To extend our findings to authentic SARS-CoV-2 virions, we repeated the above VSV-S experiments using SARS-CoV-2 Omicron variant (CoV2-S<sub>omi</sub>) (<xref ref-type="bibr" rid="c35">35</xref>, <xref ref-type="bibr" rid="c36">36</xref>), containing inserted <italic>mCherry</italic> gene and A647- or A490-labeled envelop proteins (CoV2<italic><sub>mCherry</sub></italic>-S<sub>Omi</sub>- A647 or CoV2<italic><sub>mCherry</sub></italic>-S<sub>Omi</sub>-A490). In addition, we replaced S in VSV-S with S<sub>omi</sub> for comparison between wildtype (VSV<italic><sub>EGFP</sub></italic>-S-A647) and omicron variants (VSV<italic><sub>EGFP</sub></italic>-S<sub>omi</sub>-A647). Three sets of evidence suggest that the authentic SARS-CoV-2 entry path is similar to VSV-S.</p>
<p>First, VSV-S (<xref rid="fig1" ref-type="fig">Figs. 1B-E</xref> and 1G), Lenti-S<sub>omi</sub> (<xref rid="fig1" ref-type="fig">Fig. 1F-G</xref>), VSV-S<sub>omi</sub> (<xref rid="fig4" ref-type="fig">Fig. 4A-B</xref>), and CoV2-S<sub>Omi</sub> (<xref rid="fig4" ref-type="fig">Fig. 4C-D</xref>) all exhibited hACE2-independent viral internalization, but hACE2- dependent viral gene (<italic>EGFP</italic> or <italic>mCherry</italic>) expression. Second, similar to VSV-S (<xref rid="fig2" ref-type="fig">Fig. 2A-D</xref>), 1-5 CoV2-S<sub>omi</sub> virions were found in ∼150-700 nm vesicles in the cytoplasm (<xref rid="fig4" ref-type="fig">Fig. 4E</xref>, 18 cells, 2 experiments). Third, analogous to VSV-S (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>), removing HS by HPRase nearly abolished cell-surface-attached CoV2-S<sub>omi</sub> (<xref rid="fig4" ref-type="fig">Fig. 4F</xref>). Based on these observations, we conclude that SARS-CoV-2 enters cells indistinguishably to VSV-S.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Fig 4.</label>
<caption><title>SARS-CoV-2 cell entry path is analogous to pseudo-typed SARS-CoV-2.</title>
<p><bold>A,</bold> Images (bright field and confocal images) of VSV<italic><sub>EGFP</sub></italic>-S<sub>omi</sub>-A647’s V-A647 (left) and F<sub>647</sub> (right, viral uptake) in BHK<sub>hACE2</sub> (146 cells, 3 experiments) or BHK (149 cells, 3 experiments) cells. Top: incubation protocol – VSV<italic><sub>EGFP</sub></italic>-S<sub>omi</sub>-A647 1 h at 37°C (for virus endocytosis). <bold>B,</bold> Images (bright field and confocal images) of VSV<italic><sub>EGFP</sub></italic>-S<sub>omi</sub>-A647’s <italic>V-EGFP</italic> (left) and F<italic><sub>EGFP</sub></italic> (right, viral gene expression) in BHK<sub>hACE2</sub> (273 cells, 3 experiments) or BHK (200 cells, 3 experiments) cells. Top: incubation protocol – VSV<italic><sub>EGFP</sub></italic>-S<sub>omi</sub>-A647 1 h, 24 h washout, all at 37°C (for viral gene expression). <bold>C,</bold> Images (bright field and confocal images) of CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647’s A647 fluorescence (V- A647, left) and F<sub>647</sub> (right, uptake) in BHK<sub>hACE2</sub> (120 cells, 3 experiments) or BHK (120 cells, 3 experiments) cells. Top: incubation protocol – CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 1 h at 37°C (for virus endocytosis). <bold>D,</bold> Images (bright field and confocal images) of CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647’s <italic>mCherry</italic> expression (<italic>V- mCherry</italic>, pseudo color, left) and F<italic><sub>mCherry</sub></italic> (right, uptake) in BHK<sub>hACE2</sub> (120 cells, 3 experiments) or BHK (120 cells, 3 experiments) cells. Top: incubation protocol – CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 1 h, 6 h washout, all at 37°C (for viral gene expression). <bold>E,</bold> STED XY-plane images of CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647’s V-A647 and A490 in cytosol showing that the number (N<sub>A647</sub>) of V-A647 spots (virions) in a A490 spot (endocytic vesicle) may vary as labelled. Top: incubation protocol – CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 1 h at 4°C, 3 min washout with 500- 750 μM A490 at 37°C. <bold>F,</bold> Images (bright field and confocal images) of CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 ’s V-A647 (left) and surface F<sub>647</sub> per cell (right) for BHK<sub>hACE2</sub> cells in Ctrl (120 cells, 3 experiments) or treated with HPRase (120 cells, 3 experiments). Top: incubation protocol – CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 1 h at 4°C for cell-surface attachment.</p></caption>
<graphic xlink:href="674976v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2f">
<title>Structural arrangement of HS as the SARS-CoV-2 attachment receptor</title>
<p>We characterized HS topology at molecular resolution to better understand its function as the virus receptor. 3D confocal imaging of immunolabelled HS revealed 563 ± 38 HS-spots per BHK<sub>hACE2</sub> cell-surface (range: 244-860 spots, 16 cells, 4 experiments, <xref rid="fig5" ref-type="fig">Fig. 5A</xref>). Given an average cell-surface area of 3412 ± 360 μm<sup>2</sup> (14 cells, <xref ref-type="supplementary-material" rid="supp1">Fig. S6</xref>), this amounts to an average of 1 HS-spot per 6 μm<sup>2</sup> (or 1 per 2.5×2.5 μm<sup>2</sup>). 2-D MINFLUX imaging (∼3- nm localization precision) (<xref ref-type="bibr" rid="c16">16</xref>) revealed oval-shaped clusters of HS molecules labeled by Flux 647-conjugated anti-HS antibody (HS-Ab-F647); cluster width (parallel to PM) and height (vertical to PM) were 36-243 (133 ± 6 nm) and 63-407 nm (202 ± 10 nm, 53 clusters, 9 cells, <xref rid="fig5" ref-type="fig">Figs. 5B-D</xref> and S7A-C). Although individual molecules spread between clusters were also observed (<xref rid="fig5" ref-type="fig">Fig. 5B</xref>), MINFLUX-detected HS-clusters corresponded to confocally resolved HS-spots at the PH-mNeonGreen (PH<sub>mNG</sub>)-labeled plasma membrane (<xref rid="fig5" ref-type="fig">Fig. 5B</xref>). Virus (CoV2-S<sub>omi</sub> or VSV-S) incubation resulted in virion colocalization with MINFLLUX-detected HS-clusters (<xref rid="fig5" ref-type="fig">Fig. 5C</xref>) or confocally resolved HS-spots (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>), indicating that SARS-CoV-2 virions dock at HS-clusters rather than individual HS molecule alone.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Fig 5.</label>
<caption><title>Structural arrangement of HS as the viral receptor at the cell surface.</title>
<p><bold>A,</bold> Confocal (CONF) XY-plane images of immunolabelled HS (A647-conjugated secondary antibody) at various Z-axis locations as labeled (16 cells, 4 experiments). <bold>B,</bold> MINFLUX (2D) pixel-based rendering of immunolabelled HS (HS-Ab-F647, see Methods), the corresponding confocal (CONF) image of immunolabelled HS, and confocal PH<sub>mNG</sub> (labeling PM) image at a BHK<sub>hACE2</sub> cell surface [extracellular (Extra) compartment is above the PM]. <bold>C,</bold> MINFLUX image of immunolabelled HS and STED image of CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A490 (Virus) at a BHK<sub>hACE2</sub> cell surface (merged at the bottom). Cells were incubated with CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>- A490 for 1 h at 4°C for viral cell-surface attachment. Top is the extracellular side. <bold>D,</bold> MINFLUX coordinate-based rendering of HS clusters at the cell surface with each trace ID (TID) labeled in different colors (four different regions are shown). Extra: extracellular side; PM: plasma membrane position. <bold>E, Left:</bold> MINFLUX pixel-based rendering (upper) and confocal image (lower) of immunolabelled (HS-Ab-F647) single HS molecules in vitro (on the coverslip). <bold>Right:</bold> MINFLUX coordinate-based rendering of single HS molecules color-coded by trace IDs (TIDs) (data I, II, III, IV from left panel). <bold>F,</bold> Distribution of HS-molecule number per HS-cluster (N<sub>HS</sub>/cluster, 51 clusters, 8 cells, 3 experiments). <bold>G,</bold> MINFLUX pixel-based rendering (upper) and confocal image (lower) of CoV2-S<sub>omi</sub> (CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647’s A647) at the cell surface (extracellular side: above the confocal spots). Cells were incubated with CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 for 1 h at 4°C for viral cell-surface attachment. <bold>H,</bold> MINLFUX coordinate-based rendering of CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 showing three individual virions from panel G (I, II, III in panel G). <bold>I,</bold> SARS-CoV-2 cell-entry model: heparan sulfate molecules in clusters protruding tens to hundreds of nanometers from the plasma membrane serve as the receptor for viral cell- surface attachment; endocytosis is the primary route to internalize surface-attached virions. If endocytosis co-internalizes local hACE2 in the close vicinity to the heparan sulfate cluster at the cell surface, viral RNA genome can be released from endosomes for viral genome expression to infect cells.</p></caption>
<graphic xlink:href="674976v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The mean diameter [(width+length)/2] of the cell-surface HS-Ab-F647 cluster (168 ± 8 nm, 53 clusters, 9 cells; <xref ref-type="supplementary-material" rid="supp1">Fig. S7A, B</xref>, see also <xref rid="fig5" ref-type="fig">Fig. 5D</xref>) was much larger than that of single HS-Ab-F647 molecule <italic>in vitro</italic> (26 ± 1 nm, 67 molecules, <xref rid="fig5" ref-type="fig">Figs. 5E</xref>; S7D and S7E), suggesting that each cell-surface HS cluster is composed of many single HS molecules. Normalizing the number of Flux 647 emission bursts (trace ID) per cell-surface cluster (73 ± 8, from 51 clusters, <xref ref-type="supplementary-material" rid="supp1">Fig. S7C</xref>) onto that per single molecule (2.0 ± 0.2, 67 molecules, <xref ref-type="supplementary-material" rid="supp1">Fig. S7F</xref>) yielded 38 ± 4 HS-molecules per cell-surface cluster (range: 6 - 137, 51 clusters, 8 cells, <xref rid="fig5" ref-type="fig">Fig. 5F</xref>). The number is likely higher due to steric limitations to antibody binding with individual HS molecules in the cluster.</p>
<p>Importantly, confocally resolved CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 spots corresponded to clusters of MINFLUX-resolved CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647’s A647 localizations (<xref rid="fig5" ref-type="fig">Fig. 5G</xref>). Many clusters measured ∼70-130 nm in mean diameter (<xref rid="fig5" ref-type="fig">Figs. 5G</xref> and <xref rid="fig5" ref-type="fig">5H</xref>), agreeing with SARS-CoV-2 virion diameter of ∼100 nm (<xref ref-type="bibr" rid="c4">4</xref>); some were larger (<xref rid="fig5" ref-type="fig">Fig. 5G</xref>), likely representing multiple virions. These MINFLUX-resolved SARS-CoV-2 images verified our virus labeling strategy (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>).</p>
</sec>
<sec id="s2g">
<title>SARS-CoV2 JN.1 variant binds to heparan sulfate, not hACE2, in primary human airway cells</title>
<p>To test whether our findings with the engineered Omicron variant (CoV2<sub>mCh</sub>-S<sub>omi</sub>) extend to a clinically relevant strain, we examined the JN.1 subvariant (BA.2.86.1.1) virion binding in Chinese hamster ovary (CHO) cell lines with glycosaminoglycan (GAG) deficiencies, the CHO- pgs-745 and CHO-pgsB-618 cells, in both of which heparan sulfate biosynthesis is blocked by loss of xylosyltransferase-2 (XYLT2) or β-1,4-galactosyltransferase-7 (B4GALT7) activity (<xref ref-type="bibr" rid="c37">37</xref>, <xref ref-type="bibr" rid="c38">38</xref>)(<xref ref-type="bibr" rid="c39">39</xref>). Consistent with our previous observations, Alexa 647-labeled JN.1 variant (CoV2-S<sub>JN.1</sub>- A647) showed robust binding to wild-type CHO-K1 cells, but a ∼81-84% decrease in binding in both CHO-pgsA-745 and CHO-pgsB-618 cells lacking HS (<xref rid="fig6" ref-type="fig">Fig. 6A-B</xref>). These results indicate that HS is critical for CoV2-S<sub>JN.1</sub>-A647 attachment to the cell surface.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Fig 6.</label>
<caption><title>Attachment of SARS-CoV-2 JN.1 variant at the cell surface depends on heparan sulfate.</title>
<p><bold>A,</bold> CoV2-S<sub>JN.1</sub>-A647 attachment at the cell surface: sampled bright field and confocal images of CoV2-S<sub>JN.1</sub>-A647’s V-A647 in wild-type CHO cells (CHO-K1), GAGs-deficient CHO-pgsA- 745 cells lacking HS, and GAGs-deficient CHO-pgsB-618 cells lacking HS (images merged in the right) after incubation of CoV2-S<sub>JN.1</sub> for 1 h at 4°C for labeling cell-surface attachment (incubation protocol shown on the top). <bold>B,</bold> Quantification of CoV2-S<sub>JN.1</sub>-A647 attachment at the cell surface: cell-surface fluorescence of CoV2-S<sub>JN.1</sub>-A647 (F<sub>647</sub>) per cell (mean + s.e.m.) in CHO-K1 (117 cells, 2 repeats), CHO- pgsA-745 (93 cells, 2 repeats), and CHO-pgsB-618 cells (90 cells, 2 repeats). ***: p &lt; 0.001 (ANOVA test).</p></caption>
<graphic xlink:href="674976v1_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To further test the clinical relevance, we pre-treated normal human bronchial/tracheal epithelial (NHBE) cells with: 1) control solution, 2) pixantrone (PIX), a drug under clinical trial that binds HS to inhibit HS binding with proteins (<xref ref-type="bibr" rid="c10">10</xref>), or 3) anti-hACE2 antibody that blocks CoV2-S<sub>JN.1</sub>-A647 binding with ACE2 (<xref ref-type="bibr" rid="c4">4</xref>). Immunostaining of nucleocapsid protein (N protein) and spike showed that PIX nearly abolished the cell-surface attachment of CoV2-S<sub>JN.1</sub>-A647, while anti-hACE2 antibody had no effect compared to control (<xref rid="fig7" ref-type="fig">Fig. 7A</xref>), suggesting that HS, but not ACE2 mediates authentic SARS-CoV-2 cell-surface attachment. Confocal and STED images showed the colocalization of HS and CoV2-S<sub>JN.1</sub>-A647 (<xref rid="fig7" ref-type="fig">Fig. 7B</xref>). Analogous to HS colocalization with VSV-S (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>) or CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub> (<xref rid="fig5" ref-type="fig">Fig. 5C</xref>), this result (<xref rid="fig7" ref-type="fig">Fig. 7B</xref>) suggests that HS binds CoV2-S<sub>JN.1</sub>-A647, mediating CoV2-S<sub>JN.1</sub>-A647 attachment on the NHBE cell surface.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Fig 7.</label>
<caption><title>SARS-CoV-2 JN.1 variant attachment and infection in primary human airway cells depend on HS and are inhibited by a clinically used HS-binding agent.</title>
<p><bold>A, Images for virus attachment:</bold> bright field, confocal, and merged images of CoV2-S<sub>JN.1</sub>- A647 in normal human bronchial/tracheal epithelial cells (NHBE) pre-treated with control (Ctrl), pixantrone (PIX), or anti-ACE2 antibody (ACE2 Ab). Top: incubation protocol – CoV2-S<sub>JN.1</sub>-A647 1 h at 4°C for cell-surface attachment. <bold>Bar graph for virus attachment:</bold> cell-surface fluorescence of CoV2-S<sub>JN.1</sub>-A647 (F<sub>647</sub>) per cell for normal human bronchial/tracheal epithelial (NHBE) cells pre-treated with control (Ctrl, 16 cells, 2 experiments), pixantrone (PIX, 18 cells, 2 experiments), or anti-ACE2 antibody (ACE2 Ab, 24 cells, 2 experiments). ***: p &lt; 0.001 (ANOVA test). <bold>B,</bold> Cell-surface-attached viruses colocalized with HS puncta: confocal images of viral spots (CoV2-S<sub>JN.1</sub>-A647’s V-647, red) and immunolabelled HS (Alexa 488-conjugated antibody, green) at NHBE cell surface (images merged in the bottom). Top: incubation protocol – CoV2-S<sub>JN.1</sub>-A647 1 h at 4°C for cell-surface attachment. <bold>C,</bold> PIX, but not ACE2 antibody, inhibits CoV2-S<sub>JN.1</sub> attachment in human primary small airway epithelial cells in air-liquid interface (ALI) format. <bold>Images:</bold> sampled confocal images of Hoechst (gray, labeling cell nucleus), antibody-labeled Nucleocapsid protein (N Protein of CoV2-S<sub>JN.1</sub>, green), and Spike protein (anti-S2P6 of CoV2-S<sub>JN.1</sub>, red) in ALI cells were incubated with CoV2-S<sub>JN.1</sub> for 1 h at 4°C (for viral cell- surface attachment, protocol shown at the top). Before virus incubation, cells were pretreated with 1) control solution (Ctrl), 2) Pixantrone (PIX), or 3) anti-ACE2 antibody (ACE2 Ab). Images were projection images. <bold>Bar graphs:</bold> quantification of the fluorescence of immunolabelled nucleocapsid protein (F<sub>N</sub> <sub>protein</sub>, upper) and spike (F<sub>Spike</sub>, lower) for ALI cells incubated with CoV2-S<sub>JN.1</sub> for 1 h at 4°C in three pre-treated conditions stated above (Ctrl: 2 experiments; PIX: 2 experiments; ACE2 Ab: 2 experiments). ***: p &lt; 0.001 (ANOVA test). <bold>D,</bold> Both PIX and ACE2 antibody inhibit CoV2-S<sub>JN.1</sub> infection of ALI cells. <bold>Images:</bold> Immunolabeled N-protein images from ALI cells being incubated with viruses with a protocol for viral genome expression in three conditions, including 1) control (Ctrl), 2) pretreated with PIX (before virus incubation), and 3) pretreated with ACE2 Ab. The images are from the entire ALI culture using 20x objective (scale bar: 1 mm). Incubation protocol (shown at the top): CoV2-S<sub>JN.1</sub> incubation for 1 h at 4°C, followed by incubation at 37°C for 24 h. <bold>Bar graph:</bold> quantification of the fluorescence of immunolabelled N protein (anti- Nucleocapsid protein antibody) for ALI cells being incubated with CoV2-S<sub>JN.1</sub> with a protocol for viral genome expression (protocol shown in the left) in three conditions stated above (Ctrl: 3 repeats; PIX: 3 repeats; ACE2 Ab: 3 repeats). ***: p &lt; 0.001 (ANOVA test).</p></caption>
<graphic xlink:href="674976v1_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Next, we validated our findings in a physiologically relevant human model with primary human airway epithelial cells cultured at air-liquid interface (ALI) format. Similar to results observed in NHBE cells (<xref rid="fig7" ref-type="fig">Fig. 7A, B</xref>), immunostaining for nucleocapsid protein and spike confirmed that PIX, but not anti-hACE2 antibody, substantially reduced surface-associated viral signals after the incubation protocol (4°C for 1 h) for virus cell-surface attachment (<xref rid="fig7" ref-type="fig">Figs. 7C</xref>, S8). Cell outlines were not clear at ALI format, because cells are densely packed in many layers (<xref ref-type="supplementary-material" rid="supp1">Fig. S8</xref>), making imaging difficult to resolve each cell’s outline and thus the virus distribution along the cell plasma membrane (<xref rid="fig7" ref-type="fig">Fig. 7C</xref>). However, this result reflects virus cell-surface attachment, because 1) the 4°C-for-1-h incubation protocol allowed for largely virus attachment at the cell surface as shown in <xref rid="fig3" ref-type="fig">Figs. 3</xref> and <xref rid="fig6" ref-type="fig">6</xref>, 2) inhibition of cell-surface HS-binding (<xref rid="fig6" ref-type="fig">Fig. 6</xref>), but not hACE2, substantially reduced the virus signal after the incubation for surface attachment (<xref rid="fig7" ref-type="fig">Fig. 7C</xref>), and 3) inhibition of either HS-binding or hACE2 substantially reduced the virus signal after an incubation protocol for virus infection (<xref rid="fig7" ref-type="fig">Fig. 7D</xref>).</p>
<p>For <xref rid="fig7" ref-type="fig">Fig. 7D</xref>, we assessed CoV2-S<sub>JN.1</sub> infection in primary human small airway epithelial cells cultured at ALI format, which were incubated with CoV2-S<sub>JN.1</sub> for 1 h at 4°C, followed by incubation at 37°C for 24 h for viral genome expression. Immunostaining for nucleocapsid protein revealed robust JN.1 infection in control cultures, whereas pre-treatment of PIX or anti- hACE2 antibody significantly reduced N protein signal (<xref rid="fig7" ref-type="fig">Fig. 7D</xref>). This result (<xref rid="fig7" ref-type="fig">Fig. 7D</xref>), together with the attachment data (<xref rid="fig6" ref-type="fig">Figs. 6</xref>, <xref rid="fig7" ref-type="fig">7A-C</xref>), suggests that HS mediates initial cell-surface binding with CoV2-S<sub>JN.1</sub>, while hACE2 contributes at a downstream step required for infection.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<sec id="s3a">
<title>A two-receptor entry model – HS for attachment/endocytosis and ACE2 for downstream</title>
<p>We used a variety of advanced microscopic methods, including confocal, STED, MINFLUX, and EM imaging of pseudotyped (<xref rid="fig1" ref-type="fig">Figs. 1</xref>-<xref rid="fig3" ref-type="fig">3</xref>) and authentic SARS-CoV-2 (<xref rid="fig4" ref-type="fig">Figs. 4</xref> and <xref rid="fig5" ref-type="fig">5</xref>), HS, hACE2, as well as SARS-CoV-2-containing endocytic vesicles. This revealed HS as the SARS- CoV-2 receptor underlying virus cell-surface attachment and subsequent endocytic internalization, whereas hACE2, the generally believed SARS-CoV-2 receptor (<xref ref-type="bibr" rid="c4">4</xref>), is only required after virus attachment and endocytic internalization to promote viral genome expression (summarized in <xref rid="fig5" ref-type="fig">Fig. 5I</xref>). Clusters of ∼6-137 HS molecules, not single HS molecules, are the docking site for SARS-CoV-2 attachment (<xref rid="fig3" ref-type="fig">Figs. 3</xref> and <xref rid="fig5" ref-type="fig">5</xref>). The cell surface is covered by extremely dense clusters (∼1 cluster per 6 μm<sup>2</sup>) protruding from the plasma membrane by up to ∼410 nm (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). This nanoscale arrangement – the tall, anionic HS-concentrated clusters densely covering the cell surface – may significantly enhance the chance that HS molecules in clusters bind multivalently to basic virion surface amino acids. We propose that HS outcompetes ACE2, which extends less than 10 nm from the plasma membrane (<xref ref-type="bibr" rid="c40">40</xref>), for virion attachment (<xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c21">21</xref>, <xref ref-type="bibr" rid="c41">41</xref>, <xref ref-type="bibr" rid="c42">42</xref>).</p>
<p>Although hACE2 is not required for SARS-CoV-2 attachment and endocytosis, it is required for viral genome expression (<xref rid="fig1" ref-type="fig">Fig 1</xref>). It has been suggested that hACE2 binding changes S conformation to enable the protease cleavage of S needed for viral fusion (<xref ref-type="bibr" rid="c4">4</xref>). Cell-surface hACE2 co-internalized with SARS-CoV-2 in endosomes (<xref rid="fig3" ref-type="fig">Fig. 3I</xref>) may thus promote infection by changing S conformation, allowing endosomal cathepsin L to cleave S (<xref rid="fig5" ref-type="fig">Fig. 5I</xref>). Taken together, our results suggest a new SARS-CoV-2 entry model with two receptors: HS clusters serve as the docking site for virus attachment and subsequent endocytic internalization, while hACE2 promotes downstream genome expression (<xref rid="fig5" ref-type="fig">Fig. 5I</xref>). We verified this model for clinically relevant SARS-CoV2 JN.1 subvariant binding on the cell-surface with HS and subsequent infection in primary human airway cells (<xref rid="fig6" ref-type="fig">Figs. 6</xref>, 7). Such cell surface attachment and infection were inhibited by a clinically used HS-binding agent, pixantrone (<xref rid="fig7" ref-type="fig">Fig. 7</xref>), suggesting that interfering with HS-binding is a key therapeutic strategy for COVID-19.</p>
<p>Our model (<xref rid="fig5" ref-type="fig">Fig. 5I</xref>) is novel in three aspects compared to the generally accepted current model (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c10">10</xref>). First, the current model considers hACE2 essential in mediating viral attachment and initiation of endocytosis, whereas our model does not. Second, the current model considers HS as an attachment factor augmenting hACE2’s role in binding viruses for attachment and initiation of subsequent endocytosis, whereas our model considers HS as the receptor for viral attachment and subsequent endocytosis. Third, the current model considers virus-hACE2 binding and its facilitation by HS at the cell surface before endocytosis, whereas our model moves these actions downstream of endocytosis, likely in the endosomal membrane, the principal site of virion entry.</p>
<p>Although our novel SARS-CoV-2 entry model (<xref rid="fig5" ref-type="fig">Fig. 5I</xref>) differs from the widely accepted model, our findings do not necessarily contradict previous findings underpinning the dominant model. hACE2 binding with S in vitro (<xref ref-type="bibr" rid="c5">5</xref>–<xref ref-type="bibr" rid="c7">7</xref>) and its pivotal role in infection (<xref ref-type="bibr" rid="c8">8</xref>) led to the current view that hACE2 is the receptor for SARS-CoV-2 cell-surface attachment and subsequent entry into cells (<xref ref-type="bibr" rid="c4">4</xref>), despite the lack of direct observation of SARS- CoV-2 binding with hACE2 at the cell surfaces. Although light microscopic imaging showed S and hACE2 at the plasma membrane (<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c43">43</xref>), limited resolution precluded demonstrating a direct association. We clearly showed the cell-surface association of VSV-S and SARS-CoV-2 with HS, but not ACE2 (<xref rid="fig3" ref-type="fig">Figs. 3</xref> and <xref rid="fig5" ref-type="fig">5</xref>). This finding is consistent with previous studies showing HS binding with S <italic>in vitro</italic> and inhibition of SARS-CoV-2 infection by perturbing this binding with existing drugs or heparins, despite these results leading to proposing HS as an attachment factor facilitating S binding to the cell-surface ACE2 (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c9">9</xref>–<xref ref-type="bibr" rid="c11">11</xref>).</p>
<p>Our observation of the large size (115 - 789 nm) of vesicles containing 1-5 virions suggests that the endocytosis involved may form large vesicles. This form of endocytosis could be macropinocytosis, which can form large vesicles to engulf multiple virions. Consistent with this suggestion, a recent study showed that a macropinocytosis inhibitor, EIPA, reduces SARS- CoV-2 replication in Vero cells (<xref ref-type="bibr" rid="c27">27</xref>). Our finding that viral genome (<italic>V-EGFP</italic>) expression was largely inhibited (by ∼80%) or nearly abolished by inhibition of endocytosis or endosomal cathepsin L crucial for SARS-CoV-2 endosomal fusion (<xref rid="fig2" ref-type="fig">Fig. 2</xref>) suggests endocytic internalization as the major pathway for SARS-CoV-2 genome expression. While we cannot completely rule out a minor role for viral fusion at the plasma membrane in viral genome expression, our data indicates endocytosis following HS-mediated viral cell-surface attachment as the primary pathway for SARS-CoV-2 infection in the cells we studied.</p>
</sec>
<sec id="s3b">
<title>The two-receptor model’s potential clinical relevance and broader significance</title>
<p>Interfering with HS binding has been suggested as a therapeutic strategy to prevent and treat many viral infections that depend on HS for entry, including COVID-19 (<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c12">12</xref>). However, this strategy has not been the focus for developing methods to prevent and treat COVID-19, likely because HS is considered only a regulator that is not essential for SARS- COV-2 entry. Our new model with HS as the essential attachment receptor re-emphasizes the importance of perturbing virus-HS binding, the first step of the viral entry, to efficiently block SARS-CoV-2 infection. Further supporting this view, inhibition of HS binding with a clinically used HS-binding agent, pixantrone, inhibits clinically relevant SARS-CoV-2 JN.1 subvariant binding with HS on the cell-surface and infection in primary human airway cells (<xref rid="fig6" ref-type="fig">Figs. 6</xref>, 7).</p>
<p>These results suggest a combinatorial anti-SARS-CoV-2 strategy: early HS blockade to prevent attachment combined with ACE2 targeting to inhibit post-attachment steps.</p>
<p>Analogous to SARS-CoV-2 (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c9">9</xref>–<xref ref-type="bibr" rid="c11">11</xref>), without direct supporting evidence, HS has been considered a cell-surface attachment factor regulating other coronaviruses binding with their receptor hACE2 for attachment and subsequent cell entry (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>). This includes SARS- CoV, responsible for the SARS pandemic two decades ago, and human common cold coronavirus NL63 (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>). Our findings suggest that HS may also serve as the receptor for attachment and subsequent endocytosis of these CoVs. Perturbing virus-HS binding may be a broad anti-human CoV strategy.</p>
<p>Besides coronaviruses, HS is considered an attachment factor for and can bind to, hepatitis C virus, HIV, Ebola virus, human papillomavirus, and herpesviruses (<xref ref-type="bibr" rid="c1">1</xref>). For Ebola, HS has been proposed to deliver virions into endosomes (<xref ref-type="bibr" rid="c44">44</xref>). Our results implicate that HS may be a common cell-surface attachment receptor rather than a regulator for these viruses. This is because the anionic HS-concentrated clusters are densely packed at the cell surface and may extend hundreds of nanometers above the plasma membrane (<xref rid="fig5" ref-type="fig">Fig. 5</xref>) for easy access and strong binding with basic residues of approaching viruses’ surface proteins. Docking at the HS cluster may thus be a general strategy for many viruses to attach to the cell surface. Interfering with HS binding (<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c9">9</xref>, <xref ref-type="bibr" rid="c12">12</xref>) may constitute a general anti-viral strategy for not only HS/hACE2- dependent coronaviruses, but also many other HS-dependent viruses mentioned above. For SARS-CoV-2 and other HS-binding respiratory viruses, nasal spray delivery of HS competitors or heparinase may be an inexpensive but effective general anti-viral strategy.</p>
</sec>
</sec>
<sec id="s6">
<title>Methods</title>
<sec id="s6a">
<title>Cell lines, primary cells and air-liquid interface (ALI) airway epithelial cell culture</title>
<p>We used baby hamster kidney fibroblast BHK21 (BHK, ATCC, #CCL-10), human embryonic kidney 293T (293T, ThermoFisher Scientific, R70007), African green monkey kidney Vero E6 (Vero, ATCC, #C1008 [clone E6]), Hela (ATCC, #CCL-2), and human lung fibroblast MRC5 (ATCC, #CCL-171) cells. We generated BHK21 cells stably expressing human ACE2 (BHK<sub>hACE2</sub>) and 293T cells stably expressing human ACE2 (293T<sub>hACE2</sub>) using the Sleeping Beauty transposon plasmid expression system (<xref ref-type="bibr" rid="c45">45</xref>). All cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, 11885084) supplemented with 10% fetal bovine serum (FBS, Gibco, 10082147) and incubated at 37°C and 5% CO<sub>2</sub> in a humidified incubator. Wild-type CHO-K1 (ATCC, #CCL-61) and glycosaminoglycan (GAG)-deficient mutants CHO- pgsA-745 (ATCC, #CCL-2242) and CHO-pgsB-618 (ATCC, #CCL-2241) were maintained in F- 12K medium (Gibco, 21127022) supplemented with 10% fetal bovine serum and 1% MEM NEAA (Gibco, 11140050) and incubated at 37°C and 5% CO<sub>2</sub> in a humidified incubator.</p>
<p>We generated 293T cells stably expressing T7 polymerase and VSVG (293T-T7-VSVG) for vesicular stomatitis virus (VSV) virion production and Vero cells stably expressing human transmembrane serine protease 2 (Vero-TMPRSS2) for authentic SARS-CoV-2 virion production, using the Sleeping Beauty transposon plasmid expression system (<xref ref-type="bibr" rid="c45">45</xref>). Cell lines were confirmed to be mycoplasma-free using MycoStrip detection kit (InvivoGen, rep-mys-50).</p>
<p>Normal human bronchial/tracheal epithelial cells (Lonza, CC-2540) were expanded in PneumaCult-Ex Plus Basal medium (Stemcell, #05041) in flasks and incubated at 37°C and 5% CO<sub>2</sub> in a humidified incubator. Differentiated primary human airway epithelial cultures were purchased from Epithelix (MucilAir) and maintained per the manufacturer’s instructions. Upon receipt, inserts were equilibrated for 24-48 h at 37 °C, 5% CO₂ with MucilAir™ medium (MA medium, Epithelix) in the basolateral chamber (typical volume 500–600 µL per insert), with no liquid on the apical side. MA medium was replaced 2–3 times per week. Before assays, the apical surface was gently rinsed twice with warm DPBS to remove accumulated mucus. Only well-differentiated tissues with robust ciliary beating and intact morphology were used.</p>
</sec>
<sec id="s6b">
<title>Generation of pseudo-typed SARS-CoV-2 virions: VSV<italic><sub>EGFP</sub></italic>-S-A647, VSV<italic><sub>EGFP</sub></italic>-S-A490, VSV<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647 and Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647</title>
<p>Generation of recombinant vesicular stomatitis virus (containing <italic>EGFP</italic>- coding RNA in the genome) pseudo-typed with SARS-CoV-2’s wildtype S-protein (S) of Wuhan-hu-1 strain with two modifications (VSV<italic><sub>EGFP</sub></italic>-S), the C-terminal 21 amino acids deletion and a furin cleavage site mutation R685S, was performed as previously described (<xref ref-type="bibr" rid="c46">46</xref>). Its use in tissue culture at biosafety level 2 was approved by the Institutional Biosafety Committee (IBC) at The National Institute of Allergy and Infectious Diseases (NIAID). Plasmid-based rescue of VSV<italic><sub>EGFP</sub></italic>-S was carried out as described previously with some modifications. Briefly, 293T-T7- VSVG cells in a 6-well plate were transfected with the VSV<italic><sub>EGFP</sub></italic>-S antigenome plasmid, along with plasmids expressing codon-optimized T7 polymerase (T7opt in pCAGGS, addgene, 65974), and VSV N, P, L and G-expressing plasmids (Addgene, 64087, 64088, 64085 and 8454), using TransIT-LT1 transfection reagent. The medium was exchanged with fresh DMEM containing doxycycline (1 μg/mL, for VSVG expression). EGFP expression was monitored every day for 2-3 days. Transfected cells with EGFP-positive clusters and typical cytopathic effect (CPE) were collected as passage 0 and then inoculated to fresh BHK<sub>hACE2</sub> cells to propagate as viral stock P1, which underwent further propagations to generate the VSV<italic><sub>EGFP</sub></italic>-S virions in Vero or BHK<sub>hACE2</sub> cells. Viral passages were subjected to Sanger and next-generation sequencing to verify the S gene or the viral genome.</p>
<p>VSV<italic><sub>EGFP</sub></italic>-S virus was amplified in Vero or BHK<sub>hACE2</sub> cells. The amplified VSV<italic><sub>EGFP</sub></italic>-S virus was either concentrated with an ultrafast centrifuge, or Lenti-X concentrator (Takara, #631232) according to the manufacturer’s protocol. The protein level of VSV<italic><sub>EGFP</sub></italic>-S virus was ∼6 μg/μl, which was measured with a NanoDrop spectrophotometer (ND-1000).</p>
<p>Purified VSV<italic><sub>EGFP</sub></italic>-S was incubated with Alexa Flour 647 NHS ester (A647, 7.7 μM, Invitrogen, #A20006) with gentle agitation for ∼1.5 h at 22-24°C, which led to A647 conjugation with primary amines of superficial envelop proteins of virus (VSV<italic><sub>EGFP</sub></italic>-S- A647). Free A647 dyes were removed with 7 k molecular weight cutoff desalting columns (7 k MWCO, Thermo, #89882). Viruses were aliquoted and stored at -80°C for further experiments. The resulting virion, VSV<italic><sub>EGFP</sub></italic>-S-A647, could be observed with fluorescent imaging of A647 (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>).</p>
<p>In some experiments, we replaced wildtype S protein in VSV<italic><sub>EGFP</sub></italic>-S-A647 with the omicron variant to produce the VSV<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647 virion; we replaced A647 in VSV<italic><sub>EGFP</sub></italic>-S- A647 with Atto 490LS NHS ester (A490, 63 μM, Atto-Tec GmbH, #AD 490LS-25) to produce the VSV<italic><sub>EGFP</sub></italic>-S-A490 virion.</p>
<p>Lentivirus (with <italic>EGFP</italic>-coding sequence in the genome) pseudo-typed with S protein omicron variant (Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>) was purchased from BPS Bioscience (#78624-2). Lenti<italic><sub>EGFP</sub></italic>- S<sub>Omi</sub> was incubated with A647 (7.7 μM) for ∼1.5 h at 22-24°C, and purified with desalting columns, which led to A647 conjugation with primary amines of superficial envelop proteins. The resulting virion was termed Lenti<italic><sub>EGFP</sub></italic>-S<sub>Omi</sub>-A647.</p>
</sec>
<sec id="s6c">
<title>Generation of recombinant SARS-CoV-2 omicron variant</title>
<p>The generation of recombinant SARS-CoV-2 omicron variant (CoV2-S<sub>Omi</sub>) and its use in tissue culture at biosafety level 3 were approved by the IBC and the Dual Use Research of Concern Institutional Review Entity (DURC-IRE) at NIAID. Genetic modification inserted a mCherry gene to the nucleoprotein via a 2A linker, derived from a bacterial artificial chromosome-based SARS-CoV-2 reverse genetic system (referred to as CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>) (<xref ref-type="bibr" rid="c46">46</xref>). Virus rescue experiments were performed as previously described (<xref ref-type="bibr" rid="c46">46</xref>). Briefly, BHK<sub>ACE2</sub> cells were transfected with pBAC-SARS-CoV-2 and media were changed with DMEM containing 2% FBS 6 h later. mCherry-positive cells were detached and collected along with supernatant during 48-72 h and stored at -80°C as the first stock. The stock was centrifuged to remove cell debris and used to infect fresh Vero-TMPRSS2 cells for 48-72 h. The supernatant was collected and stored at -80°C as the second stock. After the rescued virus in the second stock was confirmed by Sanger sequencing, the virus in the first stock was allowed to undergo two rounds of propagation to generate the CoV2<italic><sub>mCh</sub></italic>-S<sub>Omi</sub> virions. The viral genome sequence was verified by next-generation sequencing before virus labeling with fluorescent dyes.</p>
<p>Purified CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub> was incubated with Alexa Flour 647 NHS ester (A647, 7.7 μM, Invitrogen, #A20006) for ∼1.5 h at 22-24°C, which led to A647 conjugation with primary amines of superficial envelop proteins. The resulting virion, CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647, was purified with desalting columns (7 k MWCO, Thermo, #89882). CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 could be observed with confocal, STED, and MINFLUX imaging of A647 (<xref rid="fig4" ref-type="fig">Figs. 4</xref> and <xref rid="fig5" ref-type="fig">5</xref>). In some experiments, we replaced A647 in CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A647 with Atto 490LS NHS ester (A490, Atto- Tec GmbH, #AD 490LS) to produce CoV2<italic><sub>mCh</sub></italic>-S<sub>omi</sub>-A490.</p>
</sec>
<sec id="s6d">
<title>Preparation of SARS-CoV-2 JN.1 variant and fluorescent labeling</title>
<p>A clinically isolated JN.1 subvariant (BA.2.86.1.1) of SARS-CoV-2 (CoV2-S<sub>JN.1</sub>) was propagated under BSL-3 conditions. Purified CoV2-S<sub>JN.1</sub> was incubated with Alexa Flour 647 NHS ester (A647, 7.7 μM, Invitrogen, #A20006) for ∼1.5 h at 22-24°C, which led to A647 conjugation with primary amines of superficial envelop proteins. The resulting virion, CoV2-S<sub>JN.1</sub>-A647, was purified with desalting columns (7 k MWCO, Thermo, #89882). For some binding and infection assays, unlabeled JN.1 stocks were used.</p>
</sec>
<sec id="s6e">
<title>Plasmids, transfection, cell plating, and fluorescent dyes</title>
<p>The hACE2-TagBFP plasmid was purchased from Addgene (#164219). The mutant Dynamin 2- K44A-mCherry plasmid was created from Dynamin 2-mCherry (Addgene, #27689). The PH<sub>mNG</sub> (phospholipase C delta PH domain attached with mNeonGreen) construct was created by replacing the EGFP tag of PH-EGFP (obtained from Dr. Tamas Balla) with mNeonGreen (Allele Biotechnology) (<xref ref-type="bibr" rid="c47">47</xref>).</p>
<p>Cells were transfected with Lipofectamine LTX reagent (ThermoFisher Scientific, #A12621) according to the manufacturer’s protocol and plated on the collagen-coated glass bottom of dishes (MatTek, #P35GCol-1.5-14-C). Images were taken 48 hours after transfection.</p>
<p>We incubated cells with 50 μM A490 for 1 h to identify internalized vesicles with confocal imaging. We incubated cells with 500-750 μM A490 for 3 min for the measurement of the internalized vesicle size with STED microscopy.</p>
</sec>
<sec id="s6f">
<title>Immunostaining for confocal or STED imaging</title>
<p>Cells were fixed with 4% paraformaldehyde, blocked with 2% BSA in PBS solution for 1 h at 22-24°C, and subsequently incubated with primary and secondary antibodies. Primary antibodies were diluted in PBS containing 2% BSA and incubated with cells at 4°C for 16-20 h. After 3 times wash in PBS, cells were incubated with fluorescence-conjugated secondary antibodies for 1 h at 22-24°C. After washing 3 times with PBS, cells were mounted on confocal and STED microscopes to acquire images. Primary antibodies used here included goat anti-ACE2 (1:500, R&amp;D, #AF933), mouse anti-heparan sulfate (1:500, Amsbio, 10E4), human anti-S2P6 (1:500) and rabbit anti-nucleocapsid (1:500, GeneTex, GTX135357); secondary antibodies included Alexa Flour 647-labeled donkey anti-goat IgG (Thermo, #A21447) and Alexa Flour 568-labeled goat anti-human IgG (Thermo, #A21090), Alexa Flour 488-labeled goat anti-mouse IgG (Thermo, #A11029), Alexa Flour 488-labeled goat anti-rabbit IgG (Thermo, #A11028), Alexa Flour 488-labeled donkey anti-mouse IgM (Jackson, #715-545-140).</p>
</sec>
<sec id="s6g">
<title>Confocal imaging</title>
<p>Confocal images were acquired with Leica TCS SP8 inverted confocal microscope (Leica, Germany) equipped with a × 63/1.40 oil immersion objective. Alexa 647 (A647), EGFP, A490 and mCherry were excited by solid-state lasers with wavelength of 638 nm (30 mW output), 488 nm (20 mW output), 514 nm (20 mW output) and 552 nm (20 mW output) respectively, and their fluorescence signals were collected with Leica HyD detectors at 650- 795 nm, 500-550 nm, 560-630 nm, and 650-795 nm, respectively. To visualize the viruses labeled by A647 or A490, 638 nm or 514 nm laser was set at 0.2–2% or 5% of the maximum power; to detect virus <italic>EGFP</italic> or <italic>mCherry</italic> expression, 488 nm or 552 nm excitation laser was set at 0.5–2% or 50% of the maximum power, respectively.</p>
<p>To measure virus attachment or endocytosis, or virus genome (<italic>EGFP/mCherry</italic>) expression, XY-plane scanning along the Z-axis every 1 μm was performed (XY/Z<sub>stack</sub> scanning), and the projected fluorescence were quantified with Fiji software for each cell to quantify all the particles at cell surface or inside the cell, or the total fluorescence.</p>
<p>To measure HS puncta number at cell surface or total area of cell surface, XY/Z<sub>stack</sub> scanning with a Z-axis interval of 0.5-1 µm was performed to obtain the images of the entire cell. 3D reconstruction was generated and analyzed using Spots or Surfaces function with Imaris software (Oxford Instruments).</p>
</sec>
<sec id="s6h">
<title>STED imaging</title>
<p>The STED images were acquired with XY-plane scanning mode at a fixed Z-axis focal plane. STED images were acquired with the Abberior Expertline system based on an inverted Olympus IX83 microscope that is equipped with a UPlanSApo 100 x 1.4 NA oil immersion objective. To measure virus (VSV<italic><sub>EGFP</sub></italic>-S-A647 or CoV2<italic><sub>mCherry</sub></italic>-S<sub>Omi</sub>-A647) endocytosis with bath A490 (<xref rid="fig2" ref-type="fig">Fig. 2A-D</xref> and <xref rid="fig4" ref-type="fig">Fig. 4E</xref>), A647 and A490 were excited at 640 nm and 512 nm respectively, and both collected at 650-765 nm. STED depletion was conducted with 775 nm depletion beam at 5-10% of the maximum depletion power. XY/Z<sub>stack</sub> imaging with Z-axis interval of 200 nm was performed.</p>
<p>To measure viral colocalization with heparan sulfate and hACE2 on the cell surface, cells were incubated with VSV<italic><sub>EGFP</sub></italic>-S-A490 at 4°C for 1 h, fixed with 4% paraformaldehyde, and stained with primary and secondary antibodies. For STED imaging of VSV<italic><sub>EGFP</sub></italic>-S-A490 and heparan sulfate (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>), mouse anti-heparan sulfate (1:500, Amsbio, 10E4) and Alexa flour 488-labeled donkey anti-mouse IgM (Jackson, #715-545-140) were used to label heparan sulfate. We first acquired VSV<italic><sub>EGFP</sub></italic>-S-A490 STED images with 775 nm depletion laser together with heparan sulfate-Alexa 488 (A488) confocal images, and then both STED and confocal images of heparan sulfate-Alexa 488 were acquired with 595 nm depletion laser. VSV<italic><sub>EGFP</sub></italic>-S-A490 and heparan sulfate-A488 were excited by 640 nm and 512 nm laser, respectively, and their fluorescence signals were collected at 650-765 nm and 528-585 nm, respectively. The power of 640-nm laser was set at 3-5% of the maximum (maximum power: 1 mW); the corresponding 775 nm depletion laser power was set at 5-10% of the maximum (maximum power: 3 W). The power of 512-nm laser was set at 3-5% of the maximum (maximum power: 1 mW); the corresponding 595 nm depletion laser power was set at 5-10% of the maximum (maximum power: 700 mW).</p>
<p>For imaging of VSV<italic><sub>EGFP</sub></italic>-S-A490 and hACE2 (<xref rid="fig4" ref-type="fig">Fig. 4H-I</xref>), goat anti-ACE2 (1:500, R&amp;D, #AF933) and Alexa flour 647-labeled donkey anti-goat IgG (Thermo, #A-21447) were used to label hACE2. We acquired VSV<italic><sub>EGFP</sub></italic>-S-A490 and ACE2-Alexa 647 (A647) STED images with 775 nm depletion laser. VSV<italic><sub>EGFP</sub></italic>-S-A490 and ACE2-A647 were sequentially excited by 512 nm and 640 nm laser, respectively, and their fluorescence signals were sequentially collected at 650-765 nm. The power of 512-nm and 640-nm laser were set at 3-5% of the maximum and the 775 nm depletion laser power was set at 5-10% of the maximum.</p>
<p>STED images were deconvolved using Huygens software (Scientific Volume Imaging) as described previously (<xref ref-type="bibr" rid="c48">48</xref>) and analyzed with Image J and LAS X (Leica).</p>
</sec>
<sec id="s6i">
<title>Electron microscopy</title>
<p>BHK<sub>hACE2</sub> cells were incubated with VSV<italic><sub>EGFP</sub></italic>-S at 4°C for 1 h, then transferred to 37°C for 15 min (to track VSV<italic><sub>EGFP</sub></italic>-S in intracellular vesicles, <xref rid="fig2" ref-type="fig">Fig. 2E</xref>). BHK<sub>hACE2</sub> cells were fixed with 4% glutaraldehyde (freshly prepared, Electron microscopy sciences, Hatfield, PA) in 0.1 N Na- cacodylate buffer for 1 h at 22-24°C, and stored in 4°C refrigerator till processing. Cells were washed with 0.1 N cacodylate buffer and treated with 1% OsO4 in cacodylate buffer at 4°C for 1 h, then with 0.25% uranyl acetate (pH 5.0) at 4°C for 16-20 h. Next, cells were dehydrated with ethanol, and embedded in epoxy resin. Thin (70 nm) sections were counterstained with uranyl acetate and lead citrate and then imaged in a JEOL 200 CX TEM. Images were captured with a CCD digital camera system (XR-100 from AMT, Danvers, MA) at a primary magnification of ×10,000-30,000.</p>
</sec>
<sec id="s6j">
<title>Reagents and their application procedures</title>
<p>Dynasore (DnS, 80 μM, Millipore Sigma) (<xref ref-type="bibr" rid="c49">49</xref>, <xref ref-type="bibr" rid="c50">50</xref>) was applied to the cell media 30 min before the virus was applied, and was continuously present for another 1 h during which the virus was added to the cell media (see Fig. 2F, G for the viral incubation protocol). Cathepsin inhibitor 1 (CPS Inh, 10 μM, Selleckchem, S2847) (<xref ref-type="bibr" rid="c31">31</xref>–<xref ref-type="bibr" rid="c34">34</xref>) was applied to the cell media 30 min before the virus was applied; CPS Inh was continuously present for another 1 h (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>, left) during which the virus was added to the cell media, or for another 24 h (<xref rid="fig2" ref-type="fig">Fig. 2H-I</xref>, right) during which the virus was added for 1 h and then washed out.</p>
<p>HPRase (<xref ref-type="bibr" rid="c35">35</xref>), the heparinase I/II/III mixture containing heparinase I (3.2 units, NEB, #P0735S), heparinase II (1 units, NEB, #P0736S) and heparinase III (0.19 units, NEB, #P0737S), was applied to cells in FBS-free DMEM at 30°C for 1 h before the virus was applied. After washing out, cells were either fixed for immunostaining of heparan sulfate (<xref rid="fig3" ref-type="fig">Fig. 3D</xref>) and hACE2 or incubated with viruses at 4°C for 1 h. Virus attachment was measured after 1 h incubation at 4°C (Fig. 3E and Fig. 4F). Cells were then put back to 37°C incubator for another 1 h to measure the virus uptake (<xref rid="fig3" ref-type="fig">Fig. 3F</xref>), or for another 24 h to measure the <italic>EGFP</italic> gene expression (Fig. 3G).</p>
<p>Pixantrone (PIX, 20 µM, Selleck), a HS-binding agent under clinical trial (<xref ref-type="bibr" rid="c46">46</xref>), or anti- human ACE2 monoclonal antibody (ACE2 Ab, 20 µg/mL, R&amp;D, #AF933) was applied to the cells 30 min before the virus was applied and was continuously present for another 1 h during which the virus was added to the cell media (see <xref rid="fig7" ref-type="fig">Fig. 7A, C</xref> for the viral incubation protocol). For ALI tissues, excess apical mucus was gently removed with warm PBS (1–2 rinses) prior to incubation. Plates with inserts were pre-chilled and PIX or ACE2 Ab was applied to the apical surface and maintained during attachment or infection. After incubation, cells were washed with ice-cold medium to remove unbound virions. Inserts were immediately fixed with 4% PFA for immunostaining for binding assay (<xref rid="fig7" ref-type="fig">Fig. 7C</xref>) or changed to culture at 37 °C for 24 h, then fixed with 4% PFA for immunostaining for infection assay (<xref rid="fig7" ref-type="fig">Fig. 7D</xref>).</p>
</sec>
<sec id="s6k">
<title>Flow cytometry</title>
<p>To measure viral attachment, BHK<sub>hACE2</sub> or BHK cells were incubated with or without VSV<italic><sub>EGFP</sub></italic>- S-A647 at 4°C for 1 h, washed three times with PBS, incubated with ice-cold DPBS (Gibco) supplemented with EDTA solution (5 mM, QualityBiologicals) for 30 min. Cells were rigorously pipetted to generate single-cell suspensions (<xref ref-type="supplementary-material" rid="supp1">Fig. S5</xref>). To measure viral infection on linked samples, BHK<sub>hACE2</sub> or BHK cells were then incubated with or without VSV<italic><sub>EGFP</sub></italic>-S-A647 at 37°C for 24 h. After incubation, cells were washed with PBS three times and resuspended in DPBS (Gibco) supplemented with BSA (0.1%) (<xref ref-type="supplementary-material" rid="supp1">Fig. S2</xref>). Flow cytometry was performed on BD FACSCelesta Cell Analyzer with BD FACSDiva software version 9.0. Initial data processing was done with FlowJo version 10.10. For all flow cytometry experiments, we did not include trypsin for digestion to avoid the potential impact of trypsin in cleaving proteins attached to heparan sulfate (<xref ref-type="bibr" rid="c51">51</xref>).</p>
</sec>
<sec id="s6l">
<title>Verification of VSV<italic><sub>EGFP</sub></italic>-S-A647 in vitro</title>
<p>To visualize VSV<italic><sub>EGFP</sub></italic>-S (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>), a glass-bottomed cell culture dish was coated with lectin (Sigma) at 37°C for 1 h, and then 10 µl VSV<italic><sub>EGFP</sub></italic>-S-A647 was spread onto glass and followed by fixation with 2% paraformaldehyde at 22-24°C for 30 min. After washing, 2% bovine serum albumin (BSA)/PBS was used for block and antibody staining. VSV<italic><sub>EGFP</sub></italic>-S-A647 were incubated with anti-spike antibody (1A9, 5 µg/ml, Cat. No. GTX632604, GeneTex) targeting S2 subunit at 4°C for 16-20 h, followed by wash and 1 h of incubation with Alexa Fluor 488- labeled donkey anti-mouse IgG (Abcam). After the final wash, images (e.g., <xref rid="fig1" ref-type="fig">Fig. 1A</xref>) were acquired under a Leica TCS SP8 inverted confocal microscope (Leica, Germany) equipped with a × 63/1.40 oil immersion objective.</p>
</sec>
<sec id="s6m">
<title>MINFLUX nanoscopy</title>
<sec id="s6m1">
<title>MINFLUX data acquisition</title>
<p>MINFLUX imaging was performed on a commercial 3D MINFLUX microscope that was operated by the Imspector software with MINFLUX drivers (Abberior Instruments) (<xref ref-type="bibr" rid="c15">15</xref>). Generally, fields of view with multiple gold beads were chosen and locked in a 3D set position for active sample stabilization using the near-infrared scattering from gold beads and active feedback correction via the piezo stage. It was ensured that the standard deviation of the sample position relative to the stabilization set point was less than 2 nm in all directions during measurements. Fields of view were chosen close to the coverslip surface at the bottom of cells. Before starting the MINFLUX data acquisition, the fluorophores were driven into the dark state (cyanine-thiol adduct) using iterative confocal scans with the 640 nm excitation laser and a power between 8-15% (maximum power at periscope: 1.94 mW). The sample was imaged with the standard MINFLUX imaging sequence provided by the manufacturer using 10% fixed laser power. During the MINFLUX measurement, the 405 nm activation laser power was ramped up slowly from 0% to 50% over several hours (maximum power at periscope: 27 μW). Samples were usually imaged for ∼2-6 hours.</p>
</sec>
<sec id="s6m2">
<title>MINFLUX data analysis</title>
<p>The raw final valid molecule position estimates were exported directly from the MINFLUX Imspector interface as a .mat file. Custom MATLAB analysis software was then used to identify and segregate clusters of localizations. The data were filtered to remove trace IDs (TIDs, group of localizations originating from the same fluorophore emission burst) with a standard deviation of more than 10 nm and less than three localizations per trace (<xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c53">53</xref>).</p>
<p>For the estimate of the copy number of HS labelled with HS-antibody-A647, the TIDs per purified HS molecule <italic>in vitro</italic> were counted and used to normalize the number of TIDs per HS cluster at the cell-surface, assuming an unchanged A647 emission behavior between measurements <italic>in vitro</italic> and on the cell surface. Here, we did not count the molecules directly using the number of TIDs per cell-surface HS cluster, due to the reversibility of A647 photoswitching which would lead to overcounting. The diameter of each cluster of localizations was estimated by averaging the height and the width of an ellipse fit [(height + width)/2, Figs. S7A and S7D]. The diameter may refer to localizations for a single HS molecule in vitro, a cell- surface HS cluster, or a virion.</p>
</sec>
</sec>
<sec id="s6n">
<title>Sample preparation for MINFLUX imaging</title>
<sec id="s6n1">
<title>Preparing heparan sulfate on coverslips</title>
<p>For the attachment of heparan sulfate to coverslips, 400 µl heparan sulfate (Sigma-Aldrich, H7640) solution (1 µg/µl) was added to the glass-bottom dishes coated with collagen (MatTek, P35GCol-1.5-14-C) and allowed to stay at 4 °C for 16-20 h to adhere to the glass surface. After washing with PBS, the heparan sulfate on coverslips was blocked with 2% BSA in PBS for 1 h at 22-24 °C, followed by 1 h incubation of mouse anti-heparan sulfate (1:500, Amsbio, 10E4). Dishes with heparan sulfate were washed with PBS and incubated with a secondary goat anti-mouse IgG antibody conjugated with Flux 647 (1:500, Abberior) for 1 h. The heparan sulfate dishes were ready for the next step after washing three times with PBS.</p>
<p>Immediately prior to the confocal and MINFLUX imaging, the dish with heparan sulfate on the glass bottom was incubated with 200 µl undiluted gold bead solution (Gold nanoparticles 150 nm, BBI solutions, SKU EM.GC150) for 5 min. After rinsing off the gold bead solution, the dish was washed with PBS for several times. An isotonic imaging buffer containing 200 mM Tris-HCl (pH 8.0), 10 mM NaCl, 10% (w/v) glucose, 63 µg/ml bovine liver catalase (Sigma-Aldrich, C1345), 393 µg/ml glucose oxidase from <italic>Aspergillus niger</italic> (type VII, Sigma-Aldrich, G2133) and 12.6 mM cysteamine (Sigma-Aldrish, 30070) was added to the glass bottom of the dish. A 25-mm coverslip (Neuvitro) was placed above the glass bottom to generate a reaction cavity, excessive imaging buffer was removed to seal the cavity before mounting the dish onto the microscope. The coverslips (above the glass bottom dishes) were sealed with Elite double 22 dental epoxy (Zhermack).</p>
</sec>
<sec id="s6n2">
<title>Preparing cells for MINFLUX imaging</title>
<p>BHK<sub>hACE2</sub> cells were transfected with PH<sub>mNG</sub> plasmid and plated on glass bottom dishes (MatTek, P35GCol-1.5-14-C). The transfected cells were allowed to express PH<sub>mNG</sub> for 24-48 h. For MINFLUX imaging of heparan sulfate (Fig. 5B- D), cells were incubated with CoV2<italic><sub>mCh</sub></italic>-S<sub>Omi</sub>-A490 at 4 °C for 1 h (for confocal imaging), fixed with 4% paraformaldehyde, and then stained with mouse anti-heparan sulfate antibody and Flux 647-conjugated goat anti-mouse secondary antibody (HS-Ab-F647, for MINFLUX imaging). For MINFLUX imaging of CoV2<italic><sub>mCh</sub></italic>-S<sub>Omi</sub>-A647 (<xref rid="fig5" ref-type="fig">Fig. 5G-H</xref>), cells were incubated with CoV2<italic><sub>mCh</sub></italic>-</p>
<p>S<sub>Omi</sub>-A647 at 4 °C for 1 h, and then fixed with 4% paraformaldehyde. Immediately prior to MINFLUX imaging, the dish was incubated with 200 µl undiluted gold bead solution (Gold nanoparticles 150 nm, BBI solutions, SKU EM.GC150) for 5 min. After rinsing off the gold bead solution, the dish was washed with PBS for several times. An isotonic imaging buffer containing 200 mM Tris-HCl (pH 8.0), 10 mM NaCl, 10% (w/v) glucose, 63 µg/ml bovine liver catalase (Sigma-Aldrich, C1345), 393 µg/ml glucose oxidase from <italic>Aspergillus niger</italic> (type VII, Sigma-Aldrich, G2133) and 12.6 mM cysteamine (Sigma-Aldrich, 30070) was added to the glass bottom to generate a reaction cavity. The coverslips (above the glass bottom dishes) were sealed with Elite double 22 dental epoxy (Zhermack).</p>
</sec>
</sec>
<sec id="s6o">
<title>Statistics</title>
<p>Data were presented as mean ± s.e.m. Replicates are indicated in results and figure legends. N represents the number of cells, A490-labeled vesicle spots, endosomes, viral spots, ACE2 or HS spots, HS clusters or experiments as indicated in results and figure legends. The statistical significance was tested with the unpaired Student’s t-test.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank Susan Cheng and Sandra Lara Moreira for EM technical support. This work was supported by NINDS Research Program (ZIA NS003009-15 and ZIA NS003105-10 to L.G.W.) and the Intramural Research Program of the National Institute of Allergy and Infectious Diseases National Institutes of Health (J.W.Y.). The contributions of the NIH author(s) were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered Works of the United States Government. However, the findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s4">
<title>Author contributions</title>
<p>S.H. X.W. and T.L. performed most experiments and participated in designing experiments; A.M., C.Y.C., S.H., J.M., and C.A.W. performed MINFLUX imaging and analysis. T.L., A.D.L. and I.K. and J.W.Y. performed experiments related to authentic SARS-CoV-2 and participated in designing experiments. R.S., Z.W. and A.J.J assisted S.H. for experiments. L.G.W. designed experiments, supervised the project, and wrote the manuscript with help from J.W.Y. and all other authors.</p>
</sec>
</sec>
<sec id="additional-files" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="supp1">
<label>Supplementary file 1.</label>
<media mimetype="application" mime-subtype="pdf" xlink:href="supp1.pdf"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names> <surname>Koehler</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Delguste</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Sieben</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Gillet</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Alsteens</surname></string-name></person-group>, <article-title>Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans</article-title>. <source>Annu Rev Virol</source> <volume>7</volume>, <fpage>143</fpage>–<lpage>165</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names> <surname>Lebsir</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Zoulim</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Grigorov</surname></string-name></person-group>, <article-title>Heparanase-1: From Cancer Biology to a Future Antiviral Target</article-title>. <source>Viruses</source> <volume>15</volume>, (<year>2023</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names> <surname>Cagno</surname></string-name>, <string-name><given-names>E. D.</given-names> <surname>Tseligka</surname></string-name>, <string-name><given-names>S. T.</given-names> <surname>Jones</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Tapparel</surname></string-name></person-group>, <article-title>Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?</article-title> <source>Viruses</source> <volume>11</volume>, (<year>2019</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. B.</given-names> <surname>Jackson</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Farzan</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Choe</surname></string-name></person-group>, <article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>23</volume>, <fpage>3</fpage>–<lpage>20</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M. J.</given-names> <surname>Moore</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Vasilieva</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Sui</surname></string-name>, <string-name><given-names>S. K.</given-names> <surname>Wong</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Berne</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Somasundaran</surname></string-name>, <string-name><given-names>J. L.</given-names> <surname>Sullivan</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Luzuriaga</surname></string-name>, <string-name><given-names>T. C.</given-names> <surname>Greenough</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Choe</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Farzan</surname></string-name></person-group>, <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source>Nature</source> <volume>426</volume>, <fpage>450</fpage>–<lpage>454</lpage> (<year>2003</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Shang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Ye</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wan</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Luo</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Aihara</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Geng</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Auerbach</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Li</surname></string-name></person-group>, <article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title>. <source>Nature</source>, (<year>2020</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Lan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Shan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Fan</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name></person-group>, <article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>. <source>Nature</source> <volume>581</volume>, <fpage>215</fpage>–<lpage>220</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names> <surname>Hoffmann</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kleine-Weber</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Schroeder</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Kruger</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Herrler</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Erichsen</surname></string-name>, <string-name><given-names>T. S.</given-names> <surname>Schiergens</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Herrler</surname></string-name>, <string-name><given-names>N. H.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Nitsche</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Muller</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Drosten</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Pohlmann</surname></string-name></person-group>, <article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>. <source>Cell</source> <volume>181</volume>, <fpage>271</fpage>–<lpage>280.e278</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. M.</given-names> <surname>Clausen</surname></string-name>, <string-name><given-names>D. R.</given-names> <surname>Sandoval</surname></string-name>, <string-name><given-names>C. B.</given-names> <surname>Spliid</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Pihl</surname></string-name>, <string-name><given-names>H. R.</given-names> <surname>Perrett</surname></string-name>, <string-name><given-names>C. D.</given-names> <surname>Painter</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Narayanan</surname></string-name>, <string-name><given-names>S. A.</given-names> <surname>Majowicz</surname></string-name>, <string-name><given-names>E. M.</given-names> <surname>Kwong</surname></string-name>, <string-name><given-names>R. N.</given-names> <surname>McVicar</surname></string-name>, <string-name><given-names>B. E.</given-names> <surname>Thacker</surname></string-name>, <string-name><given-names>C. A.</given-names> <surname>Glass</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>J. L.</given-names> <surname>Torres</surname></string-name>, <string-name><given-names>G. J.</given-names> <surname>Golden</surname></string-name>, <string-name><given-names>P. L.</given-names> <surname>Bartels</surname></string-name>, <string-name><given-names>R. N.</given-names> <surname>Porell</surname></string-name>, <string-name><given-names>A. F.</given-names> <surname>Garretson</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Laubach</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Feldman</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yin</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Pu</surname></string-name>, <string-name><given-names>B. M.</given-names> <surname>Hauser</surname></string-name>, <string-name><given-names>T. M.</given-names> <surname>Caradonna</surname></string-name>, <string-name><given-names>B. P.</given-names> <surname>Kellman</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Martino</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Gordts</surname></string-name>, <string-name><given-names>S. K.</given-names> <surname>Chanda</surname></string-name>, <string-name><given-names>A. G.</given-names> <surname>Schmidt</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Godula</surname></string-name>, <string-name><given-names>S. L.</given-names> <surname>Leibel</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Jose</surname></string-name>, <string-name><given-names>K. D.</given-names> <surname>Corbett</surname></string-name>, <string-name><given-names>A. B.</given-names> <surname>Ward</surname></string-name>, <string-name><given-names>A. F.</given-names> <surname>Carlin</surname></string-name>, <string-name><given-names>J. D.</given-names> <surname>Esko</surname></string-name></person-group>, <article-title>SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2</article-title>. <source>Cell</source> <volume>183</volume>, <fpage>1043</fpage>–<lpage>1057.e1015</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>C. Z.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Swaroop</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>A. Q.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pradhan</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Hagen</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Luo</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Ye</surname></string-name></person-group>, <article-title>Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro</article-title>. <source>Cell Discov</source> <volume>6</volume>, <issue>80</issue> (<year>2020</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names> <surname>Bermejo-Jambrina</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Eder</surname></string-name>, <string-name><given-names>T. M.</given-names> <surname>Kaptein</surname></string-name>, <string-name><given-names>J. L.</given-names> <surname>van Hamme</surname></string-name>, <string-name><given-names>L. C.</given-names> <surname>Helgers</surname></string-name>, <string-name><given-names>K. E.</given-names> <surname>Vlaming</surname></string-name>, <string-name><given-names>P. J. M.</given-names> <surname>Brouwer</surname></string-name>, <string-name><given-names>A. C.</given-names> <surname>van Nuenen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Spaargaren</surname></string-name>, <string-name><given-names>G. J.</given-names> <surname>de Bree</surname></string-name>, <string-name><given-names>B. M.</given-names> <surname>Nijmeijer</surname></string-name>, <string-name><given-names>N. A.</given-names> <surname>Kootstra</surname></string-name>, <string-name><given-names>M. J.</given-names> <surname>van Gils</surname></string-name>, <string-name><given-names>R. W.</given-names> <surname>Sanders</surname></string-name>, <string-name><given-names>T. B. H.</given-names> <surname>Geijtenbeek</surname></string-name></person-group>, <article-title>Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans</article-title>. <source>EMBO J</source> <volume>40</volume>, <fpage>e106765</fpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Lang</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Deng</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Jiang</surname></string-name></person-group>, <article-title>Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans</article-title>. <source>PLoS One</source> <volume>6</volume>, <fpage>e23710</fpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names> <surname>Milewska</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Zarebski</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Nowak</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Stozek</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Potempa</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Pyrc</surname></string-name></person-group>, <article-title>Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells</article-title>. <source>J Virol</source> <volume>88</volume>, <fpage>13221</fpage>–<lpage>13230</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names> <surname>Shin</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Arpino</surname></string-name>, <string-name><given-names>S. A.</given-names> <surname>Villarreal</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Hamid</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>W. D.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>P. J.</given-names> <surname>Wen</surname></string-name>, <string-name><given-names>H. C.</given-names> <surname>Chiang</surname></string-name>, <string-name><given-names>L. G.</given-names> <surname>Wu</surname></string-name></person-group>, <article-title>Visualization of Membrane Pore in Live Cells Reveals a Dynamic- Pore Theory Governing Fusion and Endocytosis</article-title>. <source>Cell</source> <volume>173</volume>, <fpage>934</fpage>–<lpage>945</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names> <surname>Schmidt</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Weihs</surname></string-name>, <string-name><given-names>C. A.</given-names> <surname>Wurm</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Jansen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Rehman</surname></string-name>, <string-name><given-names>S. J.</given-names> <surname>Sahl</surname></string-name>, <string-name><given-names>S. W.</given-names> <surname>Hell</surname></string-name></person-group>, <article-title>MINFLUX nanometer-scale 3D imaging and microsecond-range tracking on a common fluorescence microscope</article-title>. <source>Nat Commun</source> <volume>12</volume>, 1478 (<year>2021</year>).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. C.</given-names> <surname>Gwosch</surname></string-name>, <string-name><given-names>J. K.</given-names> <surname>Pape</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Balzarotti</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Hoess</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ellenberg</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ries</surname></string-name>, <string-name><given-names>S. W.</given-names> <surname>Hell</surname></string-name></person-group>, <article-title>MINFLUX nanoscopy delivers 3D multicolor nanometer resolution in cells</article-title>. <source>Nat Methods</source> <volume>17</volume>, <fpage>217</fpage>–<lpage>224</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dieterle</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Haslwanter</surname> <given-names>D</given-names></string-name>, <string-name><surname>Bortz</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Wirchnianski</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Lasso</surname> <given-names>G</given-names></string-name>, <string-name><surname>Vergnolle</surname> <given-names>O</given-names></string-name>, <string-name><surname>Abbasi</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Fels</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Laudermilch</surname> <given-names>E</given-names></string-name>, <string-name><surname>Florez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mengotto</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kimmel</surname> <given-names>D</given-names></string-name>, <string-name><surname>Malonis</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Georgiev</surname> <given-names>G</given-names></string-name>, <string-name><surname>Quiroz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Barnhill</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pirofski</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Daily</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Dye</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Lai</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Herbert</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Chandran</surname> <given-names>K</given-names></string-name>, <string-name><surname>Jangra</surname> <given-names>RK</given-names></string-name></person-group>, <article-title>A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition</article-title>. <source>Cell Host Microbe</source> <volume>28</volume>, <fpage>486</fpage>-<lpage>496.e486</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. B.</given-names> <surname>Case</surname></string-name>, <string-name><given-names>P. W.</given-names> <surname>Rothlauf</surname></string-name>, <string-name><given-names>R. E.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>N. M.</given-names> <surname>Kafai</surname></string-name>, <string-name><given-names>J. M.</given-names> <surname>Fox</surname></string-name>, <string-name><given-names>B. K.</given-names> <surname>Smith</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Shrihari</surname></string-name>, <string-name><given-names>B. T.</given-names> <surname>McCune</surname></string-name>, <string-name><given-names>I. B.</given-names> <surname>Harvey</surname></string-name>, <string-name><given-names>S. P.</given-names> <surname>Keeler</surname></string-name>, <string-name><given-names>L. M.</given-names> <surname>Bloyet</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ma</surname></string-name>, <string-name><given-names>L. J.</given-names> <surname>Adams</surname></string-name>, <string-name><given-names>E. S.</given-names> <surname>Winkler</surname></string-name>, <string-name><given-names>M. J.</given-names> <surname>Holtzman</surname></string-name>, <string-name><given-names>D. H.</given-names> <surname>Fremont</surname></string-name>, <string-name><given-names>S. P. J.</given-names> <surname>Whelan</surname></string-name>, <string-name><given-names>M. S.</given-names> <surname>Diamond</surname></string-name></person-group>, <article-title>Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice</article-title>. <source>Cell Host Microbe</source> <volume>28</volume>, <fpage>465</fpage>–<lpage>474.e464</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. K.</given-names> <surname>Cureton</surname></string-name>, <string-name><given-names>R. H.</given-names> <surname>Massol</surname></string-name>, <string-name><given-names>S. P.</given-names> <surname>Whelan</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kirchhausen</surname></string-name></person-group>, <article-title>The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis</article-title>. <source>PLoS Pathog</source> <volume>6</volume>, <fpage>e1001127</fpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>X. L.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>X. G.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>H. R.</given-names> <surname>Si</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>C. L.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>H. D.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Luo</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>R. D.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>M. Q.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>X. R.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X. S.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Q. J.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Deng</surname></string-name>, <string-name><given-names>L. L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>F. X.</given-names> <surname>Zhan</surname></string-name>, <string-name><given-names>Y. Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>G. F.</given-names> <surname>Xiao</surname></string-name>, <string-name><given-names>Z. L.</given-names> <surname>Shi</surname></string-name></person-group>, <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source> <volume>579</volume>, <fpage>270</fpage>–<lpage>273</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. C.</given-names> <surname>Walls</surname></string-name>, <string-name><given-names>Y. J.</given-names> <surname>Park</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Tortorici</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Wall</surname></string-name>, <string-name><given-names>A. T.</given-names> <surname>McGuire</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Veesler</surname></string-name>, <string-name><surname>Structure</surname>, <given-names>Function</given-names></string-name></person-group>, <article-title>and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>. <source>Cell</source> <volume>183</volume>, <fpage>1735</fpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Niu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Qiao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>K. Y.</given-names> <surname>Yuen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Qi</surname></string-name></person-group>, <article-title>Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</article-title>. <source>Cell</source> <volume>181</volume>, <fpage>894</fpage>–<lpage>904.e899</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names> <surname>Shin</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wei</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Arpino</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>C. Y.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Hamid</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Shupliakov</surname></string-name>, <string-name><given-names>C. K. E.</given-names> <surname>Bleck</surname></string-name>, <string-name><given-names>L. G.</given-names> <surname>Wu</surname></string-name></person-group>, <article-title>Preformed Omega-profile closure and kiss-and-run mediate endocytosis and diverse endocytic modes in neuroendocrine chromaffin cells</article-title>. <source>Neuron</source> <volume>109</volume>, <fpage>3119</fpage>–<lpage>3134.e3115</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. G.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>C. Y.</given-names> <surname>Chan</surname></string-name></person-group>, <article-title>Membrane transformations of fusion and budding</article-title>. <source>Nat Commun</source> <volume>15</volume>, <issue>21</issue> (<year>2024</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. K.</given-names> <surname>Cureton</surname></string-name>, <string-name><given-names>R. H.</given-names> <surname>Massol</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Saffarian</surname></string-name>, <string-name><given-names>T. L.</given-names> <surname>Kirchhausen</surname></string-name>, <string-name><given-names>S. P.</given-names> <surname>Whelan</surname></string-name></person-group>, <article-title>Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization</article-title>. <source>PLoS Pathog</source> <volume>5</volume>, <fpage>e1000394</fpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Mercer</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Schelhaas</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Helenius</surname></string-name></person-group>, <article-title>Virus entry by endocytosis</article-title>. <source>Annu Rev Biochem</source> <volume>79</volume>, <fpage>803</fpage>–<lpage>833</lpage> (<year>2010</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y. Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Liang</surname></string-name>, <string-name><given-names>S. J.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Z. W.</given-names> <surname>Ye</surname></string-name>, <string-name><given-names>T. Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Na</surname></string-name>, <string-name><given-names>Y. L.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>Y. B.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yin</surname></string-name>, <string-name><given-names>X. H.</given-names> <surname>Cai</surname></string-name>, <string-name><given-names>Y. D.</given-names> <surname>Tang</surname></string-name></person-group>, <article-title>SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion</article-title>. <source>J Biol Chem</source> <volume>298</volume>, <issue>102511</issue> (<year>2022</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. G.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Hamid</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Shin</surname></string-name>, <string-name><given-names>H. C.</given-names> <surname>Chiang</surname></string-name></person-group>, <article-title>Exocytosis and endocytosis: modes, functions, and coupling mechanisms</article-title>. <source>Annu. Rev. Physiol</source> <volume>76</volume>, <fpage>301</fpage>–<lpage>331</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. L.</given-names> <surname>Chanaday</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Cousin</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Milosevic</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Watanabe</surname></string-name>, <string-name><given-names>J. R.</given-names> <surname>Morgan</surname></string-name></person-group>, <article-title>The Synaptic Vesicle Cycle Revisited: New Insights into the Modes and Mechanisms</article-title>. <source>J Neurosci</source> <volume>39</volume>, <fpage>8209</fpage>–<lpage>8216</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names> <surname>Antonny</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Burd</surname></string-name>, <string-name><given-names>P.</given-names> <surname>De Camilli</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Daumke</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Faelber</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ford</surname></string-name>, <string-name><given-names>V. A.</given-names> <surname>Frolov</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Frost</surname></string-name>, <string-name><given-names>J. E.</given-names> <surname>Hinshaw</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kirchhausen</surname></string-name>, <string-name><given-names>M. M.</given-names> <surname>Kozlov</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Lenz</surname></string-name>, <string-name><given-names>H. H.</given-names> <surname>Low</surname></string-name>, <string-name><given-names>H.</given-names> <surname>McMahon</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Merrifield</surname></string-name>, <string-name><given-names>T. D.</given-names> <surname>Pollard</surname></string-name>, <string-name><given-names>P. J.</given-names> <surname>Robinson</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Roux</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Schmid</surname></string-name></person-group>, <article-title>Membrane fission by dynamin: what we know and what we need to know</article-title>. <source>EMBO J</source> <volume>35</volume>, <fpage>2270</fpage>–<lpage>2284</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names> <surname>Asaad</surname></string-name>, <string-name><given-names>P. A.</given-names> <surname>Bethel</surname></string-name>, <string-name><given-names>M. D.</given-names> <surname>Coulson</surname></string-name>, <string-name><given-names>J. E.</given-names> <surname>Dawson</surname></string-name>, <string-name><given-names>S. J.</given-names> <surname>Ford</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Gerhardt</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Grist</surname></string-name>, <string-name><given-names>G. A.</given-names> <surname>Hamlin</surname></string-name>, <string-name><given-names>M. J.</given-names> <surname>James</surname></string-name>, <string-name><given-names>E. V.</given-names> <surname>Jones</surname></string-name>, <string-name><given-names>G. I.</given-names> <surname>Karoutchi</surname></string-name>, <string-name><given-names>P. W.</given-names> <surname>Kenny</surname></string-name>, <string-name><given-names>A. D.</given-names> <surname>Morley</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Oldham</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Rankine</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Ryan</surname></string-name>, <string-name><given-names>S. L.</given-names> <surname>Wells</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wood</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Augustin</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Krapp</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Simader</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Steinbacher</surname></string-name></person-group>, <article-title>Dipeptidyl nitrile inhibitors of Cathepsin L</article-title>. <source>Bioorg Med Chem Lett</source> <volume>19</volume>, <fpage>4280</fpage>–<lpage>4283</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I. C.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>B. J.</given-names> <surname>Bosch</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>K. H.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Ghiran</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Vasilieva</surname></string-name>, <string-name><given-names>T. S.</given-names> <surname>Dermody</surname></string-name>, <string-name><given-names>S. C.</given-names> <surname>Harrison</surname></string-name>, <string-name><given-names>P. R.</given-names> <surname>Dormitzer</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Farzan</surname></string-name>, <string-name><given-names>P. J.</given-names> <surname>Rottier</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Choe</surname></string-name></person-group>, <article-title>SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells</article-title>. <source>J Biol Chem</source> <volume>281</volume>, <fpage>3198</fpage>–<lpage>3203</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names> <surname>Simmons</surname></string-name>, <string-name><given-names>D. N.</given-names> <surname>Gosalia</surname></string-name>, <string-name><given-names>A. J.</given-names> <surname>Rennekamp</surname></string-name>, <string-name><given-names>J. D.</given-names> <surname>Reeves</surname></string-name>, <string-name><given-names>S. L.</given-names> <surname>Diamond</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Bates</surname></string-name></person-group>, <article-title>Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>, <fpage>11876</fpage>–<lpage>11881</lpage> (<year>2005</year>).</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. M.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>W. L.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>F. Y.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>W. J.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Hou</surname></string-name>, <string-name><given-names>C. F.</given-names> <surname>Fan</surname></string-name>, <string-name><given-names>R. H.</given-names> <surname>Jin</surname></string-name>, <string-name><given-names>Y. M.</given-names> <surname>Feng</surname></string-name>, <string-name><given-names>Y. C.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J. K.</given-names> <surname>Yang</surname></string-name></person-group>, <article-title>Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development</article-title>. <source>Signal Transduct Target Ther</source> <volume>6</volume>, <issue>134</issue> (<year>2021</year>).</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. D.</given-names> <surname>Lopez-Munoz</surname></string-name>, <string-name><given-names>J. J. S.</given-names> <surname>Santos</surname></string-name>, <string-name><given-names>J. W.</given-names> <surname>Yewdell</surname></string-name></person-group>, <article-title>Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>120</volume>, <fpage>e2304087120</fpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suzuki</surname> <given-names>R</given-names></string-name>, <string-name><surname>Yamasoba</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kimura</surname> <given-names>I</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kishimoto</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>J</given-names></string-name>, <string-name><surname>Morioka</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Nao</surname> <given-names>N</given-names></string-name>, <string-name><surname>Nasser</surname> <given-names>H</given-names></string-name>, <string-name><surname>Uriu</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kosugi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tsuda</surname> <given-names>M</given-names></string-name>, <string-name><surname>Orba</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sasaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Shimizu</surname> <given-names>R</given-names></string-name>, <string-name><surname>Kawabata</surname> <given-names>R</given-names></string-name>, <string-name><surname>Yoshimatsu</surname> <given-names>K</given-names></string-name>, <string-name><surname>Asakura</surname> <given-names>H</given-names></string-name>, <string-name><surname>Nagashima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sadamasu</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yoshimura</surname> <given-names>K</given-names></string-name>, <collab>Genotype to Phenotype Japan (G2P-Japan) Consortium</collab>, <string-name><surname>Sawa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ikeda</surname> <given-names>T</given-names></string-name>, <string-name><surname>Irie</surname> <given-names>T</given-names></string-name>, <string-name><surname>Matsuno</surname> <given-names>K</given-names></string-name>, <string-name><surname>Tanaka</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fukuhara</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sato</surname> <given-names>K</given-names></string-name></person-group> <article-title>Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant</article-title>. <source>Nature</source> <volume>603</volume>, <fpage>700</fpage>-<lpage>705</lpage> (<year>2022</year>).</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. D.</given-names> <surname>Esko</surname></string-name>, <string-name><given-names>J. L.</given-names> <surname>Weinke</surname></string-name>, <string-name><given-names>W. H.</given-names> <surname>Taylor</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Ekborg</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Rodén</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Anantharamaiah</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Gawish</surname></string-name></person-group>, <article-title>Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I</article-title>. <source>J Biol Chem</source> <volume>262</volume>, <fpage>12189</fpage>–<lpage>12195</lpage> (<year>1987</year>).</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. D.</given-names> <surname>Esko</surname></string-name>, <string-name><given-names>T. E.</given-names> <surname>Stewart</surname></string-name>, <string-name><given-names>W. H.</given-names> <surname>Taylor</surname></string-name></person-group>, <article-title>Animal cell mutants defective in glycosaminoglycan biosynthesis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>82</volume>, <fpage>3197</fpage>–<lpage>3201</lpage> (<year>1985</year>).</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. D.</given-names> <surname>López-Muñoz</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Kosik</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Holly</surname></string-name>, <string-name><given-names>J. W.</given-names> <surname>Yewdell</surname></string-name></person-group>, <article-title>Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity</article-title>. <source>Sci Adv</source> <volume>8</volume>, <elocation-id>eabp9770</elocation-id> (<year>2022</year>).</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Xia</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhou</surname></string-name></person-group>, <article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>. <source>Science</source> <volume>367</volume>, <fpage>1444</fpage>–<lpage>1448</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><given-names>D.</given-names> <surname>Wrapp</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>K. S.</given-names> <surname>Corbett</surname></string-name>, <string-name><given-names>J. A.</given-names> <surname>Goldsmith</surname></string-name>, <string-name><given-names>C. L.</given-names> <surname>Hsieh</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Abiona</surname></string-name>, <string-name><given-names>B. S.</given-names> <surname>Graham</surname></string-name>, <string-name><given-names>J. S.</given-names> <surname>McLellan</surname></string-name></person-group>, <article-title>Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation</article-title>. <source>bioRxiv</source>, (<year>2020</year>).</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Chopra</surname></string-name>, <string-name><given-names>X. R.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>K. M.</given-names> <surname>Bouwman</surname></string-name>, <string-name><given-names>S. M.</given-names> <surname>Tompkins</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Wolfert</surname></string-name>, <string-name><given-names>R. P.</given-names> <surname>de Vries</surname></string-name>, <string-name><given-names>G. J.</given-names> <surname>Boons</surname></string-name></person-group>, <article-title>Heparan Sulfate Proteoglycans as Attachment Factor for SARSCoV- 2</article-title>. <source>Acs Central Sci</source> <volume>7</volume>, <fpage>1009</fpage>–<lpage>1018</lpage> (<year>2021</year>).</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names> <surname>Bayati</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Kumar</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Francis</surname></string-name>, <string-name><given-names>P. S.</given-names> <surname>McPherson</surname></string-name></person-group>, <article-title>SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis</article-title>. <source>J Biol Chem</source> <volume>296</volume>, <issue>100306</issue> (<year>2021</year>).</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names> <surname>O’Hearn</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Cheng</surname></string-name>, <string-name><given-names>C. M.</given-names> <surname>Lear-Rooney</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Koning</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Rumschlag-Booms</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Varhegyi</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Olinger</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Rong</surname></string-name></person-group>, <article-title>Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry</article-title>. <source>J Virol</source> <volume>89</volume>, <fpage>5441</fpage>–<lpage>5449</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names> <surname>Kowarz</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Loscher</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Marschalek</surname></string-name></person-group>, <article-title>Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines</article-title>. <source>Biotechnol J</source> <volume>10</volume>, <fpage>647</fpage>–<lpage>653</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ye</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chiem</surname> <given-names>K</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Oladunni</surname> <given-names>F</given-names></string-name>, <string-name><surname>Platt</surname> <given-names>RN</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>T</given-names></string-name>, <string-name><surname>Almazan</surname> <given-names>F</given-names></string-name>, <string-name><surname>de la Torre</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Martinez-Sobrido</surname> <given-names>L</given-names></string-name></person-group>, <article-title>Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome</article-title>. <source>mBio</source> <volume>11</volume>, (<year>2020</year>).</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. C.</given-names> <surname>Shaner</surname></string-name>, <string-name><given-names>G. G.</given-names> <surname>Lambert</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Chammas</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Ni</surname></string-name>, <string-name><given-names>P. J.</given-names> <surname>Cranfill</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Baird</surname></string-name>, <string-name><given-names>B. R.</given-names> <surname>Sell</surname></string-name>, <string-name><given-names>J. R.</given-names> <surname>Allen</surname></string-name>, <string-name><given-names>R. N.</given-names> <surname>Day</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Israelsson</surname></string-name>, <string-name><given-names>M. W.</given-names> <surname>Davidson</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Wang</surname></string-name></person-group>, <article-title>A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum</article-title>. <source>Nat. Methods</source> <volume>10</volume>, <fpage>407</fpage>–<lpage>409</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wei</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Arpino</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Shin</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>L. G.</given-names> <surname>Wu</surname></string-name></person-group>, <article-title>Real-time visualization of exo- and endocytosis membrane dynamics with confocal and super-resolution microscopy</article-title>. <source>STAR Protoc</source> <volume>3</volume>, <issue>101404</issue> (<year>2022</year>).</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names> <surname>Macia</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Ehrlich</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Massol</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Boucrot</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Brunner</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kirchhausen</surname></string-name></person-group>, <article-title>Dynasore, a cell-permeable inhibitor of dynamin</article-title>. <source>Dev. Cell</source> <volume>10</volume>, <fpage>839</fpage>–<lpage>850</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. D.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Hamid</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Shin</surname></string-name>, <string-name><given-names>P. J.</given-names> <surname>Wen</surname></string-name>, <string-name><given-names>E. S.</given-names> <surname>Krystofiak</surname></string-name>, <string-name><given-names>S. A.</given-names> <surname>Villarreal</surname></string-name>, <string-name><given-names>H. C.</given-names> <surname>Chiang</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Kachar</surname></string-name>, <string-name><given-names>L. G.</given-names> <surname>Wu</surname></string-name></person-group>, <article-title>Hemi-fused structure mediates and controls fusion and fission in live cells</article-title>. <source>Nature</source> <volume>534</volume>, <fpage>548</fpage>–<lpage>552</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. G.</given-names> <surname>dela Paz</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Melchior</surname></string-name>, <string-name><given-names>F. Y.</given-names> <surname>Shayo</surname></string-name>, <string-name><given-names>J. A.</given-names> <surname>Frangos</surname></string-name></person-group>, <article-title>Heparan sulfates mediate the interaction between platelet endothelial cell adhesion molecule-1 (PECAM-1) and the Galphaq/11 subunits of heterotrimeric G proteins</article-title>. <source>J Biol Chem</source> <volume>289</volume>, <fpage>7413</fpage>–<lpage>7424</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. M.</given-names> <surname>Mulhall</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Gharpure</surname></string-name>, <string-name><given-names>R. M.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>A. E.</given-names> <surname>Dubin</surname></string-name>, <string-name><given-names>J. S.</given-names> <surname>Aaron</surname></string-name>, <string-name><given-names>K. L.</given-names> <surname>Marshall</surname></string-name>, <string-name><given-names>K. R.</given-names> <surname>Spencer</surname></string-name>, <string-name><given-names>M. A.</given-names> <surname>Reiche</surname></string-name>, <string-name><given-names>S. C.</given-names> <surname>Henderson</surname></string-name>, <string-name><given-names>T. L.</given-names> <surname>Chew</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Patapoutian</surname></string-name></person-group>, <article-title>Direct observation of the conformational states of PIEZO1</article-title>. <source>Nature</source> <volume>620</volume>, <fpage>1117</fpage>–<lpage>1125</lpage> (<year>2023</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. K.</given-names> <surname>Pape</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Stephan</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Balzarotti</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Buchner</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Lange</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Riedel</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jakobs</surname></string-name>, <string-name><given-names>S. W.</given-names> <surname>Hell</surname></string-name></person-group>, <article-title>Multicolor 3D MINFLUX nanoscopy of mitochondrial MICOS proteins</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>117</volume>, <fpage>20607</fpage>–<lpage>20614</lpage> (<year>2020</year>).</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.108925.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Schoggins</surname>
<given-names>John W</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7944-6800</contrib-id>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution>
</institution-wrap>
<city>Dallas</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Useful</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study presents a role for heparin sulfate in SARS-CoV-2 entry that runs counter to prevailing data in the field. If the conclusions were firmly supported by the data, the work would be a significant contribution to the field. While the use of diverse cellular models, virological tools, and robust microscopy approaches constitutes a <bold>useful</bold> data set, the proposed model remains <bold>incomplete</bold> and requires clarification of entry mechanisms, host factors, and viral variant-specific fusion pathways to substantiate it against established entry models.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.108925.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This paper investigates how heparan sulfate (HS) engagement functions in the cellular entry of SARS-CoV-2. A prevailing model that has been developed over the last five years by work from many laboratories using a variety of biochemical, structural, and microscopic approaches is that HS acts a co-receptor for SARS-CoV-2; its binding to SARS-CoV-2 both concentrates virus on the surface of target cells and allosterically alters the spike protein to promote an &quot;up/open&quot; RBD conformation that enables engagement of the proteinaceous receptor human ACE2 on the cell surface (PMID: 32970989, 35926454, 38055954, 39401361, 40548749). These two events enable plasma membrane fusion (after a cleavage event promoted by plasma membrane TMPSS2) or endocytosis and subsequent pH-dependent fusion (which requires a cathepsin L-mediated cleavage of the spike).</p>
<p>The authors in this study used a series of microscopy techniques, labeled pseudoviruses and authentic SARS-CoV-2 strains, and cells lacking or expressing HS and/or hACE2 to re-examine the specific stage(s) HS and hACE2 function in the entry process. They suggest that HS mediates SARS-CoV-2 cell-surface attachment and endocytosis, and that hACE2 functions &quot;downstream&quot; of this to facilitate productive infection. Their results also suggest that SARS-CoV-2 binds clusters of HS molecules projecting 60-410 nm, which act as docking sites for viral attachment. Blocking HS binding with pixantrone, a drug under clinical evaluation for cancer (due to its anti-topoisomerase II activity), inhibited SARS-CoV-2 Omicron JN.1 variant from attaching to and infecting human airway cells. The authors conclude that their work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting at some stage downstream. They speculate this idea might apply broadly to other viruses known to engage HS and has translational implications for developing antiviral agents that target HS interactions.</p>
<p>The strengths of the interesting and technically well-executed study include the use of multiple high-resolution microscopy modalities, the tracking of labelled viruses, the use of both pseudoviruses and authentic SARS-CoV-2, and the use of primary airway cells. Nonetheless, there are issues that need to be addressed to buttress the proposed model compared to earlier ones. These include: (a) the distinction between macropinocytosis and receptor-mediated endocytosis and what this might mean for productive SARS-CoV-2 infection; (b) the need to account for TMPRSS2 expression and plasma membrane fusion; (c) addition of genetic studies in which hACE2 is expressed in cells lacking HS; (d) an unclear picture of exactly where downstream hACE2 functions; and (e) and a need for comparative/additional study of earlier SARS-CoV-2 variants, which preferentially fuse at the plasma membrane.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.108925.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>In this manuscript by Han et al, the authors assess the binding of SARS-CoV-2 to heparan sulfate clusters via advanced light microscopy of viral particles. The authors claim that the SARS-CoV-2 spike (in the context of pseudovirus and in authentic virus) engages heparan sulfate clusters on the cell surface, which then promotes endocytosis and subsequent infection. The finding that HSPGs are important for SARS-CoV-2 entry in some cell types is well-described, but the authors attempt to make the claim here that HS represents an alternative &quot;receptor&quot; and that HS engagement is far more important than the field appreciates. The data itself appears to be of appropriate quality and would be of interest to the field, but the overly generalized conclusions lack adequate experimental support. This significantly diminishes enthusiasm for this manuscript as written. The manuscript is imprecise and far overstates the actual findings shown by the data. Additional controls would be of great benefit.</p>
<p>Further, it is this reviewer's opinion that the findings do not represent a novel paradigm as claimed. HS has been well described for SARS-CoV-2 and other viruses to serve as attachment factors to promote initial virus attachment. While the manuscript provides new insight into the details of this process, the manuscript attempts to oversell this finding by applying new words rather than new molecular details. The authors would be better served by presenting a more balanced and nuanced view of their interesting data. In this reviewer's opinion, the salesmanship significantly detracts from the data and manuscript.</p>
<p>Major Comments:</p>
<p>The authors need to rigorously define a &quot;receptor&quot; vs an &quot;attachment factor.&quot; They also should avoid ambiguous terms such as &quot;receptor underlying ...attachment&quot; and &quot;attachment receptor&quot; (or at least clearly define them). Much of their argument hinges on the specific definition of these terms. This reviewer would argue that a receptor is a host factor that is necessary and sufficient for active promotion of viral entry (genome release into the cytoplasm), while an attachment factor is a host factor that enhances initial viral attachment/endocytosis but is neither necessary nor sufficient. The evidence does NOT implicate HS as a receptor under this fairly textbook definition. This is proven in Figure 1 (and elsewhere) in which ACE2 is absolutely required for viral entry.</p>
<p>The authors should genetically perturb HS biosynthesis in their key assays to demonstrate necessity. HS biosynthesis genes have been shown to be important for SARS-CoV-2 entry into some cells but not others (Huh7.5 cells PMID 33306959, but not in Vero cells PMID 33147444, Calu3 cells 35879413, A549 cells 33574281, and others 36597481. The authors need to discuss this important information and reconcile it with their data and model if they want to claim that HS is broadly important.</p>
<p>Is targeting HS really a compelling anti-viral strategy? The data show a ~5-fold reduction, which likely won't excite a drug company. The strengths and limitations of HS targeting should be presented in a more balanced discussion. Animal data showing anti-viral activity of PIX is warranted. This would enhance this claim and also provide key evidence of a relevant role for HS in a more physiologic model.</p>
<p>The authors provide little discussion of the fact that these studies rely exclusively on cell lines (which also happen to be TMPRSS2-deficient). The role of proteases in the role of HS should be tested in the cell lines and primary cells used, as protease expression is a key determinant of the site of fusion.</p>
<p>The claim that &quot;SARS-CoV2 JN.1 variant binds to heparan sulfate, not hACE2, in primary human airway cells&quot; is extraordinary and thus requires extraordinary evidence.</p>
<p>First, PIX reduces attachment by 5-fold, which is not the same as &quot;nearly abolished.&quot; Also, anti-ACE2 &quot;nearly abolished&quot; entry in 7D, while PIX did not. If the authors want to make these claims, an alternative method to disrupt HS (other than PIX) is needed in primary airway cells. A genetic approach would be much more convincing. The authors should also demonstrate whether entry in their primary cell assays is TMPRSS2 vs Cathepsin L dependent (using E64d and camostat, for instance) as mentioned above.</p>
<p>Each figure should clearly state how many independent experiments and replicates per experiment were performed. What does &quot;3 experiments&quot; mean? Are these three independent experiments or three wells on one day?</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.108925.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this manuscript, the authors define a new paradigm for the attachment and endocytosis of SARS-CoV-2 in which cell surface heparan sulfate (HS) is the primary receptor, with ACE2 having a downstream role within endocytic vesicles. This has implications for the importance of targeting virion-HS interactions as a therapeutic strategy.</p>
<p>Strengths:</p>
<p>The authors show that viruses are internalized via dynamin-dependent endocytosis and that endocytic internalization is the major pathway for pseudotyped SARS-CoV-2 genome expression. They show that HS-mediated viral attachment is a critical step preceding viral endocytosis and also subsequent genome expression. Further, they show that hACE2 acts downstream of endocytosis to promote viral infection, and may be co-internalised with virions after HS attachment. Pseudotyped virus and authentic SARS-CoV-2 provide similar results. In addition, the authors demonstrate that remarkable clusters of multiple HS chains exist on the cell surface, visualised by a number of elegant microscopy methods, and that these represent the docking sites for virions. These visualisations are an important general contribution in themselves to understanding the nanoscale interactions of HS at the cell surface.</p>
<p>The use of a complementary range of methods, virus constructs, and cell models is a strength, and the results clearly support the conclusions.</p>
<p>Overall, the results convincingly demonstrate a different model to the currently accepted mechanism in which the ACE2 protein is regarded as the cell surface receptor for SARS-CoV-2. Here, the authors provide compelling evidence that cell surface clusters of HS are the primary docking site, with ACE2 interactions occurring later, after endocytosis (whilst still being essential for viral genome expression). This is an exciting and important landmark evidence which supports the view that HS-virion interactions should be viewed as a key site for anti-viral drug targeting, likely in strategies that also target the downstream ACE2-based mechanism of viral entry within endosomes.</p>
<p>Weaknesses:</p>
<p>This reviewer identified only minor points regarding citing and discussing other studies and typos, which can be corrected.</p>
</body>
</sub-article>
</article>